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INVESTIGATING THE ROLE OF EXOSOMAL COMMUNICATION                
WITHIN THE GLIOMA MICROENVIRONMENT
Javier Miguel Figueroa II, M.S.Supervisory Professor: Frederick F. Lang, M.D.
Evidence indicates that human cancers are maintained by a population of 
cells with stem-like properties called cancer stem cells (CSCs). However, the 
influence of the surrounding stromal cells on the behavior of the CSCs remains 
poorly understood. We have recently shown that the micro-environment of human 
gliomas, the most aggressive human brain tumors, contains both glioma stem cells 
(GSCs) and cells that resemble human bone marrow-derived mesenchymal stem 
cells (BM-MSCs), called Glioma Associated-MSCs (GA-MSCs). We have also 
shown that GA-MSCs generate a cytokine-mediated increase in the growth and self-
renewal (clonogenicity) of GSCs. However, other paracrine interactions between 
GA-MSCs and GSCs have not been fully explored. Recent studies have suggested 
that nano-sized vesicles, termed exosomes, may contribute to intercellular 
communication within the tumor niche. Therefore, I hypothesized that GA-MSC-
derived exosomesincrease the growth and evolution of gliomas. Here I show for the 
first time that exosomes can be isolated from patient-derived GA-MSCs and that 
these exosomes contain oncogenic microRNAs. Importantly, in vitro delivery of 
exosomes isolated from GA-MSCs significantly increased both the proliferation and 
clonogenicity of GSCs. Furthermore, GSC xenografts,treated with GA-MSC-derived 
exosomes, inthe brains of nude mice resulted in a greater tumor burden and 
significantly decreased animal survival. Lastly, delivery of microRNA identified as 
both highly expressed and highly enriched in GA-MSC-derived exosomes, altered 
gene expression in recipient GSCs resulting in the glioma-enhancing effects 
described. I conclude that GA-MSC-derived exosomes represent an alternative 
intercellular communication mechanism for the transfer of specific microRNAs, which 
enhance the aggressive nature of Gliomas.
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Introduction 
 
  Breakthroughs in biological science are typically the result of cutting-edge 
research exploring novel mechanisms of physiologic and pathologic processes. For 
intercellular communication, the forefront of present research has recently shifted 
from protein signal transduction to exosomal paracrine mechanisms. For cancer, the 
vanguard of current research has moved from the study of tumor propagating cells 
to the investigation of the complex interactions within the tumor micro-environment. 
These front lines of discovery converge in an area evaluating the exosomal 
paracrine intercellular signaling within the microenvironment of tumors. Considering 
the variety of possible exosomal contents, the crosstalk between tumor propagating 
cells and the surrounding tumor niche via the transfer of exosomes is likely 
paramount to that of protein receptor activation. Therefore, my research investigates 
the role of exosomal communication within the micro-environment of tumors. 
Specifically, I focused my studies on the interaction between glioma stroma-derived 
exosomes and glioma propagating cells, and the resulting effects of this 
communication pathway. This subject has never been studied in gliomas, and 
significant findings will establish a novel mechanism for communication within the 
tumor micro-environment, as well as a potential target for adjunct therapy. Given the 
complexity of cancer, the success of future curative therapies relies on a full 
understanding of tumor biology that includes evaluation of the intercellular exosomal 
communication system within the tumor microenvironment. 
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1.1 Exosome Background 
Intercellular communication has previously been characterized as the transfer 
of ions, proteins, hormones, and lipids.1-4 However, evidence for an alternative form 
of communication between neighboring cells, involving the delivery of proteomic and 
genetic elements via exosomes, is building. Exosomes are quickly being recognized 
as an important part of cell biology in both physiologic and pathologic conditions.5-9 
Therefore, in cancer research, it is essential that we evaluate this mechanism of cell-
to-cell interaction in order to move towards a more complete understanding of the 
microenvironment in which a tumor forms and progresses.  
The term exosome is used to specify a subset of small microvesicles, and is 
not to be confused with the unrelated intracellular RNA degrading exosome-
complex.10-11 Exosomes belong to a class of extracellular vesicles, and are the 
smallest in the group. An exosome is a 40-100 nm diameter particle composed of 
the same lipid bi-layer membrane from the originating cell.12 Thus the size of 
exosomes limits their analysis by light microscopy, which has a lower limit of 
approximately 200nm, and instead requires the utilization of electron microscopy.13 
Conversely, light microscopy can be used to observe larger extracellular vesicles, 
specifically microvesicles (200-1000nm in diameter) and apoptotic bodies (1-5µm in 
diameter).13 Exosomes are also found to have a density range of 1.10-1.19 g/mL, 
which differs from that of heavier microvesicles (1.17-1.25 g/mL) and apoptotic 
bodies (1.24-1.28 g/mL).13 The formation of exosomes takes place intracellularly 
within the endosomal/lysosomal system, after which they are excreted from the cell 
via exocytosis. This process also distinguishes exosomes from larger microvesicles 
and apoptotic bodies, which form by external membrane budding or blebbing, and 
fragmentation of the plasma membrane, respectively.14  
Exosomes were first described via electron microscopy (EM) in 1981 by 
Trams, et al, as a smaller subset of a group of larger microvesicles derived from the 
C-6 rat glioma cell line.15 Here, the authors were investigating the ecto-5’-
nucleotidase activity of a group of large microvesicles (500-1000nm in diameter) that 
budded from the plasma membrane of glioma cells. Their EM analysis however, 
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demonstrated the presence of a smaller subset of microvesicles (40-100nm in 
diameter) that had no ecto-5’-nucleotidase activity and did not seem to form from 
plasma membrane blebbing. Trams and colleagues were the first to propose the 
term exosomes for the nano-sized vesicles.15 Subsequently in 1983, Pan, et al, 
described a physiologic role for exosomes in the elimination of the transferrin 
receptor during reticulocyte maturation.16 Here, investigators found that mature 
sheep reticulocytes no longer required transferrin receptors to maintain intracellular 
iron homeostasis. Unutilized receptors were then recycled to endosomal 
compartments within the cell, and then excreted into the extracellular space in 
exosomes.16 These two seminal papers revealed exosomes to be a novel part of cell 
biology, and since that time the literature on exosomes has increased exponentially. 
An important part of studying exosomes is understanding how they are 
formed. This knowledge could lead to more accurate detailing of their composition, 
and help determine their function. Exosomes form within the endosomal system. 
This system is responsible for intracellular protein trafficking between various 
organelles and the cell membrane. The formation of exosomes initially involves the 
recycling of plasma membrane receptors and proteins, via clathrin-associated 
endocytosis, resulting in the extracellular domain of membrane proteins now within 
the intra-endosomal compartment. This process signifies the creation of the early 
endosomes in the cytosol (Figure 1).17 Early endosomes then follow one of two 
pathways, depending on their content and function. The first pathway involves fusion 
with a lysosome, resulting in degradation and recycling of intra-endosomal 
contents.17 The second pathway involves lysosomal escape which is thought to be 
signaled by specific endosomal membrane components. Lysosomal escape results 
in the eventual maturation of early endosomes into late endosomes.17 The 
membrane of late endosomes then undergoes the process of reverse endosomal 
budding, which is essentially endocytosis of the endosomal membrane. This process 
forms smaller vesicles within the endosome, which now have the extracellular 
domain of recycled plasma membrane proteins in the extra-vesicular compartment. 
The formation of these intra-endosomal vesicles, which are future exosomes, 
signifies the creation of the multi-vesicular body (MVB).17 MVBs then traffic their  
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Figure 1. Exosomes are formed by an intracellular 
process. (1) Clathrin-coated pit endocytosis, recycling 
plasma membrane components. (2) Formation of an 
early endosomes that escape lysosomal degradation, 
becoming a late endosome. (3) Reverse-inward 
budding resulting in exosomes within intra-endosomal 
compartment, and forming a multi-vesicular  body 
(MVB). (4) Fusion of the MVB membrane with the 
plasma membrane, releasing exosomes into the 
extracellular space.
17
 
6 
 
cargo of exosomes through the cytoplasm to the plasma membrane.17 Fusion of 
MVBs with the cell membrane occurs in an energy-dependent, calcium-mediated, 
process.18-19 This process is similar to the mechanism used by neurons to release 
pre-packaged neurotransmitter vesicles from the axon terminal into the synaptic 
space. After the MVB fuses with the plasma membrane, the exosomes are released 
with similar, but not identical, membrane receptors and proteins characteristic of the 
originating cell. Once in the extracellular milieu, exosomes are able to bind to target 
cells and complete the intercellular interaction by transferring their internal cargo.17  
 One key aspect of exosome formation that is poorly understood is the 
concentrating and packaging of specific cellular elements in the exosomal 
membrane and inside exosomes. The composition of the exosomal membrane is not 
identical to that of the cell membrane from which it was derived. Although the two 
membranes are similar to each other, exosomal membranes lack many of the 
common cluster of differentiation (CD) and fragment crystallizable (Fc) surface 
proteins, as well as various integrins, that are present on the plasma membrane.20 
Thus, the components of the membrane are altered during protein recycling and 
exosome formation, with certain lipids and proteins being removed or 
concentrated.20 For instance, compared to the cell of origin, exosomes have an 
increased concentration of ceramide, an important lipid membrane constituent 
capable of cellular signaling.21 This indicates that the composition of the exosome 
membrane is distinctive and purposeful, and is not indiscriminately compiled. 
Similarly, the intra-exosomal content is comparable, but not identical, to that of the 
parental cell.22 The packaging of cellular elements into exosomes has been linked to 
the ESCRT (endosomal sorting complex required for transport) machinery, which is 
part of the endosomal system and responsible for trafficking of proteins and 
remodeling of cellular membranes during exosome formation.23 Variations in this 
process can lead to either enrichment or depletion of exosomal content depending 
on the needs of the cell.22 For instance, specific nucleotide motifs on RNA molecules 
can be recognized by ribonucleoproteins (RNPs), which lead to the cell preferentially 
packaging messenger-RNA (mRNA) or microRNA (miRNA) into exosomes.24-26 The 
unique differences between the composition of exosomes and the cell of origin 
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indicate that exosome formation is not a random process, and that both the 
membrane constituents and intra-exosomal content are assembled for a distinct 
purpose in cellular biology. 
 Exosomes are known to contain a wide variety of cellular elements that are in 
the exosomal membrane (Figure 2).27 Likewise, the function of these membrane 
constituents is broad. Evidence shows that exosome membrane can contain 
integrins, which can mediate binding in the extracellular space and may play a role 
in internalization by a recipient cell.28-29 Additionally, studies show that the 
membranes of exosomes can contain major histocompatibility complexes (MHC) 
which can participate in antigen presentation and immune responses to infection and 
cancer.30-31 Many other membrane proteins have been described in exosomes, 
some of which have no known or accepted function at this time. Specifically, proteins 
in the tetraspanin family, which are thought to be membrane scaffold proteins, have 
been ubiquitously described in exosomes. However, the role of these proteins in 
exosomes is still under investigation. Included in the tetraspanin family are various 
cluster of differentiation proteins, including CD9, CD37, CD63, and CD81, which are 
all used as surface markers for exosomes.32-33 CD63 is one of the most utilized 
tetraspanin surface markers in exosomes from a variety of cell types, and has been 
linked to antigen presentation via association with MHC molecules.34 This 
assortment of proteins represents only a fraction of the exosomal membrane 
constituents, and new functional components are still being discovered. 
 Similar to the exosomal membrane components, the intra-exosomal 
compartment is home to a wide variety of cellular elements (Figure 2).27 However 
unlike the membrane components, the roles of nearly all cellular elements within 
exosomes are well known. The glycolytic enzyme glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) is known to play a major role in intracellular vesicular 
trafficking, and may also indicate a metabolic role for exosomes.35-36 The intra-
exosomal compartment can also contain functional genetic elements, not present in 
exosomal membranes. The transfer of mRNA via exosomes has been described in a 
variety  of  disease  processes,  including  cancer.  Once  inside  the  recipient  cell,  
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Figure 2. Exosome contain cellular elements. The 
exosomal membrane contains a variety of proteins, including 
the family of tetraspanins used as exosomal markers. The 
intra-exosomal compartment contains various cellular 
elements, including soluble proteins (GAPDH) and RNA.
27
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exosome-delivered mRNA can be translated by recipient cell machinery. Evidence 
shows that oncogenic mRNA within exosomes can enhance gene expression in non-
cancer cells, thereby modifying cellular biology.37-38 Additionally, miRNA have been 
extensively described in exosomes from numerous cell types. Once in the cytoplasm 
of the recipient cell, miRNA can regulate gene expression by binding to 
complementary regions in the 3-prime untranslated region (3’UTR) of mRNA, and 
inhibiting translation. Studies show that the exosome-mediated transfer of oncogenic 
miRNAs can alter the biology of non-cancer cells, while the transfer of tumor-
suppressor miRNAs can inhibit tumor growth.39-42 Importantly, exosome profiling has 
drastically expanded the list of known contents, which adds to the complexity of this 
intercellular communication system. 
Interaction of exosomes with recipient cells has been shown to occur in two 
distinct forms, both of which are receptor mediated: direct fusion or endocytic 
internalization (Figure 3).43 The exosomal membrane constituents include proteins 
that can serve to target exosomes to specific recipient cells. For example, exosomes 
from platelets readily bind to endothelial cells and macrophages, but not to 
neutrophils.44 This highlights the complexity of exosome function, and suggests that 
they are not universally taken up by all cell types. Thus, targeting of exosomes to a 
specific destination must be encoded into the exosomal membrane for recognition 
by a specific recipient cell type. Upon receptor interaction with the desired cell, 
exosomes can either fuse with plasma membrane or be internalized by 
endocytosis.45-46 Either pathway will eventually result in transfer of receptors to the 
cell plasma membrane, as well as the transmission of exosome contents, including 
RNA, into the cytosol.43 In the case of immediate fusion with the plasma membrane, 
the contents of the exosomes can readily interact with their cytosolic targets, for 
instance miRNA can begin to bind and inhibit mRNA gene transcripts.27 However, 
the fate of exosomes which undergo endocytosis is variable, with some exposed to 
lysosomal degradation or recycling to the extracellular space.17 Only exosomes 
which escape these degradative processes and release their content into the 
recipient cell cytoplasm, will have successfully navigated the entire exosomal 
intercellular communication pathway, to induce a targeted effect. 
10 
 
  
Figure 3. Exosomes can be taken up by target 
cells. (1) Exosome can bind receptors on the 
plasma membrane of the recipient cell, and 
initiate endocytosis for internalization into the 
cytoplasm. (2) Exosomes can fusion with the 
plasma membrane of the recipient cell, releasing 
their contents into the cytoplasm.
43
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1.2 Gliomas and Exosomes 
Exosomes were first described in the setting of cancer, therefore it is fitting 
that the majority of research since that time has been devoted to exploring their role 
in malignancy.15 To date, exosomes have been described in a wide variety of cancer 
types and in numerous aspect of tumor biology, from promoting metastases and 
malignant progression, to utilizations as diagnostic/prognostic markers, and as novel 
delivery vehicles for therapeutics.47-53 Furthermore, exosomes have been implicated 
in modulation of the immune response to tumors, subjugation of the 
microenvironment, and resistance to chemotherapy.54-59  Exosomes derived from 
lung, breast and prostate cancers are the most widely studied.60-62 However, with 
respect to gliomas, the evidence for exosome interactions within malignancies of the 
brain is less extensive.63-65 Nevertheless, the unique anatomical nature and isolated 
environment of the brain only add to the potential for significant exosomal function in 
localized tumors. 
At present time, there are a limited number of published studies pertaining to 
human gliomas and exosomes. These few reports can be grouped into three broad 
categories; reviews, basic science, and translational. The reviews sought to 
correlate the knowledge of exosomes from research areas outside the central 
nervous system, to that of gliomas.63-65 The review published by van der Vos, et al., 
focused on the changes mediated by transfer of exosomal RNA in the glioma 
microenvironment, as well as the utilization of exosomes as a diagnostic 
biomarker.63 A subsequent review by, D’asti and colleagues, addressed the 
biogenesis and characterization of exosomes in glioma, as well as the oncogenic 
potential of the exosomal cargo.64 The latest review, by Gonda, et al., concentrated 
on the modulation of the tumor microenvironment by exosomes in glioma, as well as 
the therapeutic applications for exosomes against gliomas.65 These comprehensive 
reviews cover much of the currently published research on gliomas and exosomes, 
and connect the findings with those from other areas of exosome research. 
Basic science studies investigating gliomas and exosomes, range from 
proteomic and genetic characterization of GBM exosomes to evaluating the 
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exosomal influence on tumor neo-angiogenesis.66-73 Bastida and colleague 
published the first study on gliomas and exosomes in 1984. Here researchers 
demonstrated the presence of tissue factor (TF) in exosomes derived from the U87 
human glioblastoma (GBM) line. These TF-laden GBM-derived exosomes had pro-
thrombotic capabilities, which were linked to the activation of the coagulation 
cascade and promotion of platelet aggregation.66 Svensson, et al., then 
demonstrated that TF in glioma-derived exosomes could interact with endothelial 
cells in a paracrine manner. These TF-laden glioma-derived exosomes could 
activate pro-thrombotic properties in recipient endothelial cells under hypoxic 
conditions.67 These studies highlighted the role of glioma-derived exosomes in tumor 
thrombosis. However, the majority of basic science exosome research in gliomas 
focuses on their content. In 2008, Al-Nedawi, et al., identified the mutant EGFRvIII in 
exosomes derived from glioma cells. This EGFR variant is oncogenic due to 
constitutive activity, and exosomes mediated the transfer to non-EGFRvIII 
expressing glioma cells.68 This study was the first to demonstrate exosome-
mediated transfer of tumor-promoting proteins, and laid the foundation for exosome 
characterization. The first profiling of glioma-derived exosomes was performed by 
Graner and colleagues.69 Here researchers described the presence of mutant 
EGFRvIII, as well as immunosuppressive TGF-β, within exosomes released into the 
systemic circulation by gliomas.69 Research then shifted to the genetic profiling of 
glioma-derived exosomes. Guescini, et al., showed that exosomes secreted by GBM 
cells harbored mitochondrial DNA (mtDNA), but not nuclear DNA (nDNA). These 
exosomes mediated the transfer of mtDNA to neighboring cells, which could 
modulate mitochondrial activity.70 This exosomal transfer of genetic elements 
represented a new mechanism of intercellular communication in gliomas. 
Subsequently, Bolukbasi and colleagues reported the presence of specific 
nucleotide (nt) sequences in the 3’UTR of mRNA in glioma cells that resulted in 
targeted enrichment into exosomes for transport out of the cell. This 25nt “zip-code” 
sequence also contained a complementary binding site for miR-1289, which was 
found to play a role in the enrichment process into glioma-derived exosomes.71 
Furthermore, Li, et al., identified the enrichment of non-coding RNA, particularly 
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miRNA and vault-RNA (vtRNA), in glioma-derived exosomes. Interestingly, they also 
described the miRNA profile of these exosomes as distinct compared to the glioma 
cells from which they originate.72 These studies uncovered the significant amount of 
genetic material present in glioma-derived exosomes, however this characterization 
did not yet correlate with function. In 2013, Kucharzewska and colleagues, described 
hypoxic enhancement of mitogenic and angiogenic properties in glioma-derived and 
tumor stroma-derived exosomes. When compared to normoxic conditions, glioma-
derived exosomes contained increased levels of matrix metalloproteinases (MMPs), 
IL-8 and PDGFs, when isolated under hypoxic conditions. Similarly, exosomes 
derived from hypoxic endothelial cells harbored increased levels of growth factors 
and cytokines which stimulated PI3K/AKT signaling in pericytes.73 Together, these 
basic science papers demonstrate the broad range of exosome function in gliomas, 
and highlight the need for further investigation of exosomes in other areas of glioma 
biology.      
Translational studies explored patient oriented applications from exosomal 
RNA and immunologic therapeutic strategies to the diagnostic and prognostic 
utilities of exosomes.74-81 Recently, Katakowski and colleagues found that GBM cells 
had decreased levels of miR-146b when compared to normal human astrocytes, 
which also held true for the 9L rat glioma cell line. Delivery of BM-MSC-derived 
exosomes, packaged with miR-146b, to rat glioma xenografts resulted in decreased 
tumor burden, due to miRNA-mediated EGFR down-regulation.74 Additionally, 
Munoz, et al., showed that GBM cells had low levels on miR-9, which targets the 
drug efflux transporter, P-glycoprotein. Increasing the levels of this specific miRNA in 
GBM cells, via delivery of miR-9 laden MSC-derived exosomes, resulted in the 
down-regulation of P-glycoprotein, and increased the chemosensitivity of GBM cells 
to temozolomide (TMZ).75 Furthermore, Bronisz and colleagues demonstrated that 
glioma cells had very low expression of miR-1, and that over-expression of this 
miRNA resulted in diminished tumorigenicity. Interestingly, GBM cells which were 
modified to over-express miR-1, released exosomes that were enriched in miR-1. 
These miR-1 laden GBM cell-derived exosomes decreased tube formation of human 
brain microvascular endothelial cells (HBMVECs) in vitro, as well as increased the 
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invasion of GBM cells through the extracellular matrix in vivo.76 The findings from 
these studies support the investigation and utilization of miRNA-packaged exosomes 
as a therapeutic strategy.  In the area of tumor immunology, Bu, et al., demonstrated 
that glioma-derived exosomes contained tumor antigens that were recognized by 
recipient antigen-presenting dendritic cells. After exposure to glioma-derived 
exosomes, dendritic cells were able to activate T-lymphocytes that had robust 
cytotoxic activity against autologous glioma cells.77 This study highlighted the 
potential for the use of tumor-derived exosomes as a vaccine for immunization 
against gliomas. With regard to treatment of gliomas with ionizing radiation, Arscott 
and colleagues showed the increase of connective tissue growth factor (CTGF) 
mRNA and insulin-like growth factor binding protein 2 (IGFBP2) in glioma-derived 
exosomes after glioma irradiation. Furthermore, exosomes derived from irradiated 
gliomas promoted the activation of neurotrophic tyrosine kinase receptor type 1 
(TrkA) and proto-oncogene tyrosine-protein kinase Src, in recipient non-irradiated 
glioma cells. Delivery of growth factors and kinase activation resulted in an increase 
in glioma cell migratory and invasive properties.78 This study indicates that pre-
surgical radiation of gliomas may promote further invasion of glioma cells that have 
escaped radiation-induced cell death. Thus, this mechanism may play a role in 
tumor recurrence at the surgical margins. With respect to the diagnostic properties of 
exosomes, Noerholm and colleagues found that glioma-derived exosomes, isolated 
from the serum of glioma patients, contained numerous RNA elements including a 
significant amount of small non-coding RNA species < 500nt in length. This 
exosome RNA profile was distinct from that of exosomes derived from normal 
subjects, specifically in the down-regulation of 121 genes, many of which encoded 
for ribosomal proteins.79 This study outlined the potential for profiling of intra-
exosomal content as a diagnostic approach in gliomas. However, other researchers 
sought to utilized exosomal surface markers as an alternative diagnostic method. 
Skog, et al., found that glioma-derived exosomes carried numerous mRNA, miRNA 
and angiogenic proteins, which were functional upon transfer to recipient cells in the 
tumor.80 This exosomal communication facilitated neovascularization and promoted 
proliferation of tumor stroma cells.  Interestingly, many of these glioma-derived 
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exosomes were able to escape into the circulatory system due to blood-brain barrier 
breakdown in the tumor. These circulating glioma-derived exosomes were found to 
contain glioma markers, particularly mutant EGFRvIII, and could be used as an 
adjunct diagnostic tool.80 Subsequently, Shao and colleagues, developed micro-
nuclear magnetic resonance (µNMR) techniques to analyze exosomes from the 
serum of glioma patients. When compared to serum-exosomes from normal 
subjects, those from glioma patient had increased expression of EGFR, EGFRvIII, 
podoplanin (PDPN), and mutant isocitrate dehydrogenase 1 (IDH1) R132H. Analysis 
of this panel of markers by µNMR resulted in a glioma diagnostic test with 90% 
sensitivity and 85% specificity. The glioma marker panel was also shown to have 
prognostic capabilities by predicting patient response to temozolomide 
chemotherapy.81 This important study supports the utilization of glioma-derived 
exosomes for both diagnostic and prognostic purposes. Together, the findings from 
these translational studies demonstrate the practicality and efficacy of exosome 
research towards improving patient outcomes. 
Importantly, in every basic science and translational study discussed above, 
the research is focused on investigating exosomes derived from the tumor-
propagating glioma cells and not exosomes released by cells in the surrounding 
microenvironment. To my knowledge there are no published studies evaluating the 
role of tumor stroma-derived exosomes in the development and evolution of glioma. 
Investigation into this aspect of glioma biology would add to the growing body of 
knowledge for glioma and exosomes, and is crucial to fully understand this complex 
tumor system. This will translate to more effective therapeutic strategies against 
gliomas in the future. 
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1.3 The Glioma Microenvironment  
 Cancer is the second leading cause of death in the United States, falling just 
behind heart disease, and will account for over half a million deaths in 2014. Of the 
wide range of malignant neoplasms, lung, colon, breast, pancreatic and prostate 
cancers will be responsible for nearly 55% of those fatalities.82 Rare in comparison, 
brain tumors only account for 2.5% of cancer related deaths in United States 
citizens, 80% of which will be the result of primary malignant gliomas. However, the 
incidence and prevalence of gliomas is increasing. Additionally, the course of the 
disease process is among the most devastating, with a majority of patients 
succumbing to the disease within the first year, and less than 5% living beyond 5 
years after diagnosis.83-84 Furthermore there is no way to screen for, or prevent, 
gliomas. People can avoid smoking to decrease their risk of lung cancer. Females 
can be screened for breast cancer by receiving regular mammograms. Males can be 
screened for prostate cancer by obtaining regular prostate exams. Colon cancer can 
be discovered early during routine colonoscopy screenings. These preventative and 
early diagnostic measures are not available in glioma, and patients typically present 
late in the disease process. If caught early enough, a few of the other cancer types 
can be treated with a combinations of radiation, surgery and chemotherapy, and 
many patients given the designation of “in remission” or “cured”. Unfortunately this is 
rarely the case with glioblastoma (GBM), the most common primary malignant 
glioma in adults. Instead, clinicians tend to speak realistically in terms of life 
extension rather than cancer free outcomes. Thus, these bleak results are the 
driving force for new research into the full understanding of gliomas. 
 One of the major discoveries in the last decade was the characterization of 
glioma propagating cells isolated from patient tumor samples.85-87 Investigation of 
these cells in tumor development is the focus of a majority of glioma research. 
Additionally, study of these cells aided in the development of a wide range of 
therapeutic strategies aimed at eradicating gliomas.88 However, glioma propagating 
cells are only one of the cell types present in any given tumor, with many other cells 
establishing an intricate support network termed the glioma microenvironment.89 
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 Cancer stem cells (CSCs) were first described by Bonnet and Dick in 
leukemia in 1997, and subsequently described in gliomas by Singh, et al, in 2003, 
and Galli, et al., in 2004.85-87 These cells possessed stem-like properties, particularly 
the ability to undergo asymmetric replication (self-renewal) and multi-lineage 
differentiation (potency).90 Furthermore, when compared to normal brain tissue, 
brain CSCs, also known as glioma stem cells (GSCs), expressed many genetic 
aberrations that promote cell proliferation and inhibit apoptosis. These properties 
were termed oncogenic, and subsequently linked to the presence of several tumor 
promoting genes, termed oncogenes, found in GSCs; mitogen-activated protein 
kinase (MAPK), mitogen-activated protein kinase kinase (ERK), retrovirus-
associated sequences (RAS), cellular myelocytomatosis (c-MYC), and protein 
kinase B (Akt).91-96   
 Work performed in the Lang laboratory before I joined included the isolation of 
GSCs from patient surgical specimens, by adapting the protocol published by Singh 
and colleagues.86 Briefly, after enzymatic digestion of the gross tumor sample, GSCs 
were identified by non-adherent neurosphere growth in serum-free neural stem cell 
medium (Figure 4). Isolated GSCs were also found to express the known neural 
stem cell marker CD133 (Figure 5).86 Lastly, GSCs were able to form tumors when 
implanted as xenografts into the brains of nude mice (Figure 6). Importantly, GSCs 
harbored the same genetic aberrations known to be present in many glioblastomas 
(Figure 7).96 The isolation of these GSC lines formed the basis for my future 
experiments into the glioma microenvironment and novel therapeutic strategies.97 To 
date, 40 GSC lines have been isolated, characterized, and genetically profiled. 
 After the discovery of GSCs, trials of various targeted therapeutic agents, 
including viral vectors, vaccines, and stem cell therapies, were pursued in hopes of 
decreasing the collateral damage to non-cancerous cells caused by traditional 
radiation and chemotherapy.98-99 However, the combination of surgery, radiation, 
plus concomitant and adjuvant temozolomide (TMZ) chemotherapy remains the 
standard of care for all malignant gliomas, as described by Stupp and colleagues in 
2005.100  The Stupp protocol extends survival from less than one year to nearly 15  
18 
 
  
Figure 4. GSC exhibit specific morphology in cell culture. (A) Non-
adherent growth of GSC 262 as a classical neurosphere in neural stem cell 
medium. (B) Non-adherent growth of GSC 20 as a non-classical neurocluster in 
neural stem cell medium. 
B A 
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Figure 5. GSCs express a 
glial stem cell marker. 
Flow cytometry histogram 
for GSC 262 demonstrating 
the expression of the 
CD133 neural stem cell 
marker.
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Figure 6. GSCs are tumorigenic. (A) H&E staining of histologic 
sections though the brain of untreated control mice euthanized 30 
days after the sham injection procedure, demonstrating no tumor 
growth. (B) H&E staining of histologic sections through glioma 
xenografts from mice euthanized 30 days after implantation of 
GSCs, demonstrating significant tumor growth.
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months, and since its inception there have been no studies in which outcomes have 
improved using any of the new therapeutic strategies targeted against GSCs. One 
reason may be the lack of a full understanding of the complex microenvironment of 
gliomas. This microenvironment not only involves the GSC component, but also 
includes the tumor stroma which is composed of many other cell types. 
The idea of a nurturing tumor microenvironment is not new, and was first 
postulated by the English surgeon Stephen Paget in 1889.101 In his paper, Dr. Paget 
referred to malignancy as a combination of “seed and soil”, in which neither on their 
own could grow a “plant”. Thus, the idea of a cultivating microenvironment for cancer 
cells to grow and develop into a tumor was born. Interestingly, Dr. Paget also added 
that some tumors had a predisposition for metastasis to specific organs.101 A century 
later in 1989, the “seed and soil” theory was finally validated by Halachmi and 
colleagues, when they found that the tumor microenvironment has a positive effect 
on tumor growth. Specifically, they demonstrated that cancer cells passaged in vivo, 
were more tumorigenic compared to those cultured in vitro.102  
The description of a microenvironment in gliomas was elucidated by Chen, et 
al, in 1993. In their seminal paper, researchers showed that tumor necrosis factor-
alpha (TNF-α) secreted by astrocytes in the tumor stroma, increased the proliferation 
rate of malignant astrocytoma cell lines.103 These studies outlined processes by 
which the surrounding cytoarchitecture of a tumor can significantly affect the 
progression of the disease. To date, endothelial cells, perivascular cells, immune 
cells, and organ parenchymal cells and organ stem cells have been described as 
part of this tumor niche. For gliomas, this includes the endothelium, pericytes, 
microglia, astrocytes and neural stem cells.89, 104-105 Of these cell types, each has 
been implicated in creating pro-glioma conditions in which the malignancy will thrive 
and progress. Endothelial cells, which function to maintain the blood-brain barrier in 
normal brain tissue, have been shown to secrete mitogenic factors that increase the 
self-renewal and invasiveness of GSCs.106-107 Pericytes which form a framework for 
the neuro-vasculature, have been found to stabilize tumor neovascularization as well 
as suppress the immune response to the malignancy.108-109 Microglia, which are the 
23 
 
resident immune cells in the brain, have also been found to increase tumor 
invasiveness and induce immunosuppression within gliomas.110-111 Astrocytes, the 
local parenchymal cells, can increase tumor cell survival as well as decrease the 
activation of the immune system.112-113 Finally, neural stem cells, which are capable 
of differentiating into neurons, astrocytes and oligodendrocytes, are readily recruited 
to the hypoxic environment of the tumor site. Once incorporated into the tumor 
niche, neural stem cells may undergo malignant transformation.114-115 Thus, the 
synergistic nature of tumor propagating GSCs and the nurturing glioma 
microenvironment may contribute to the inadequacy of current glioma therapy which 
does not target both. To effectively combat this devastating disease, requires full 
working knowledge not only of the genetic aberrations and tumorigenic features of 
GSCs, but also an understanding of the mechanisms by which the glioma 
microenvironment supports the malignancy. This knowledge will facilitate the 
development of more effective therapies aimed at both the tumor propagating cells 
and the tumor stroma.116 
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1.4 Glioma-Associated Mesenchymal Stem Cells 
 In 1963, Becker, McCulloch and Till first demonstrated that transplanted bone 
marrow cells in mice could undergo clonal expansion in the spleen.117 Researchers 
showed that these cells were undifferentiated, but under certain culturing conditions 
were able to differentiate along mesodermal lines. Specifically, these progenitor cells 
were able to differentiate into the mesenchymal subtypes: osteocytes, chondrocytes 
and adipocytes. Furthermore, these cells replicated by asymmetric division creating 
one clonal cell identical to the parental cell, and one daughter cell programmed for 
differentiation. These transplanted bone marrow cells were the “stem” of multiple 
mesenchymal lineages, and were termed mesenchymal stem cells (MSCs).117 
 During the evolution of MSC research, the definition of a mesenchymal stem 
cell became inconsistent and non-uniform between research groups. For this reason  
the International Society for Cellular Therapy (ISCT) established a discrete set of 
requirements to denote mesenchymal stem cells.118 In addition to MSCs being 
undifferentiated and multipotent, they must grow adherent in in vitro culture with 
spindle morphology. Furthermore, the MSCs must express the mesenchymal 
surface markers, CD73 (ecto-5’-nucleotidase), CD90 (thymocyte differentiation 
antigen-1), and CD105 (endoglin), and lack the hematopoietc stem cell marker 
CD34 (platelet/endothelial cell adhesion molecule-1), the panleukocyte marker CD45 
(protein tyrosine phosphatase, receptor type, C), and the neural stem cell marker 
CD133 (Prominin 1).119-121 These parameters ensured that research groups were 
conducting investigations utilizing a consistent and uniform definition of an MSC. 
 After the discovery of MSCs from human bone marrow (BM-MSCs), stem 
cells were found in other organ systems. Importantly, in 1989, Temple demonstrated 
progenitor cells in the subventricular zone (SVZ) of adult human brains, termed 
neural stem cells (NSCs).122 Later, research groups began exploring cancer for stem 
cells, given that tumor growth results from a clonal expansion of cells.123 After the 
discovery of cancer stem cells (CSCs) in 1997, and glioma stem cells (GSCs) in 
2003, researchers began looking for non-tumor propagating stem cells within the 
tumor stroma of various malignancies.85-86 One cell of focus in tumors was MSCs 
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due to their ability to home to sites of tissue injury to aid in wound healing.124-126 The 
similarities between tumors and chronic wounds are well established, considering 
the damage to surrounding stromal structure that occurs as a malignancy grows.127 
Therefore it is reasonable that MSCs would home to tumors to participate in tissue 
repair. In 2001, Wallace and colleagues first identified MSCs within primary sites of 
multiple myeloma.128 These tumor-associated MSCs (TA-MSCs) were found in the 
perivascular niche of the tumor and were distinct from tumor-propagating plasma 
cells in both morphology and genetic profile. TA-MSCs were subsequently described 
in breast, prostate and lung cancer.129-131 Cancer stem cells were then shown to 
produce certain chemotactic factors that promoted the recruitment of MSCs to the 
primary tumor sites.132 Additionally, the phenomenon of MSC recruitment was first 
demonstrated in vivo by Kidd and colleagues in 2009, using a mouse model to show 
the localization of systemically delivered luciferase-labeled MSCs to breast cancer 
xenografts.133 Interestingly, this homing functionality of MSCs prompted investigation 
into their use as a delivery vector for anti-cancer agents, such as interferon-β.134-135 
Thus, MSCs are now accepted as a distinct component of the tumor stroma. 
 Mesenchymal stem cells were only recently demonstrated in normal brain 
tissue by Paul and colleagues in 2012.136 Researchers found a subgroup of cells 
resembling pericytes lining the cerebral microvasculature in select areas of the brain. 
However, unlike pericytes, these cells expressed many of the mesenchymal 
markers, but lacked endothelial, microglial, hematopoietic, glial, and neural stem cell 
markers. Additionally, these cells had stem-like properties in their ability to 
differentiate along mesodermal lines.136 These results show that MSCs are present 
in the microvasculature of normal brain tissue. Since MSCs are known to migrate to 
sites of tissue injury, it is reasonable that these organ-specific MSCs may play a role 
in the acute repair of local tissue.124-126 Thus, the origin of tumor-associated MSCs 
(TA-MSC) could be from locally recruited MSCs in the tumor perivascular niche or 
from distantly recruited MSCs from the bone marrow. However, regardless of the 
origin, TA-MSCs have never been described in brain tumors. Although MSCs are 
known to migrate towards gliomas, and are used as a therapeutic delivery vehicle, 
they have never been isolated from patient-derived tumor specimens.137-142 
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 Research conducted by the Lang laboratory before I joined, focused on the 
isolation and characterization of TA-MSCs in gliomas, termed glioma-associated 
mesenchymal stem cells (GA-MSCs).97 Initially, surgical specimens were obtained 
within 4 hours of resection, and processed in accordance with the protocol published 
by Pittenger and colleagues, with a modification for whole tissues.143 Briefly, after 
enzymatic digestion of the gross tumor sample, GA-MSCs were identified by plastic-
adherent growth in serum-containing cell culture medium (Figure 8). Furthermore, 
GA-MSCs expressed the characteristic MSC markers of CD73, CD90 and CD105, 
and lacked the hematopoietc marker CD34, the panleukocyte marker CD45, and the 
neural stem cell marker CD133 (Figure 9). Lastly, GA-MSCs were able to 
differentiate into chondrocytes, adipocytes and osteocytes by growth medium 
induction (Figure 10). Importantly, GA-MSCs were genetically distinct from GSCs 
isolated from the same specimen (Figure 11), and did not form tumors when 
implanted as xenografts into the brains of nude mice (Figure 12). The discovery of 
this novel cell line in gliomas prompted further research investigating the intercellular 
interactions between GA-MSCs and GSCs, in order to elucidate their function in the 
microenvironment.97 
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Figure 8. GA-MSCs exhibit specific morphology in cell culture. (A) GA-
MSC 262 adherent growth and classical spindle morphology in MSC medium. 
(B) GA-MSC 20 adherent growth and classical spindle morphology in MSC 
medium. 
B A 
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CD73 CD90 
CD105 CD133 
Figure 9. GA-MSCs express known MSC markers. Flow cytometry 
histograms for GSC 262 demonstrating the expression of the MSC 
markers CD73, CD90 and CD105, and lack of expression of the neural 
stem cell marker CD133. 
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Figure 10. GA-MSCs can tri-differentiate along 
mesenchymal lines. Light microscopy demonstrating the 
characteristic adipocyte, osteocyte and chondrocyte 
morphology of differentiated GA-MSCs after culture in 
differential medium.
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Figure 11. Matching GSCs and GA-MSCs do not 
harbor the same genetic mutations. Chromosomal 
analysis demonstrating loss of heterogeneity for 
chromosome 10 in GSC 240, which is preserved in the 
matching GA-MSC 240 isolated from the same patient 
tumor.
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Figure 12. GA-MSCs are not tumorigenic. (A) H&E staining of 
histologic sections though the brain of untreated control mice 
euthanized 30 days after the sham injection procedure. (B) H&E 
staining of histologic sections through the brains of mice euthanized 
30 days after implantation of GA-MSCs.
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1.5 The Role of Mesenchymal Stem Cells in the Tumor Niche 
The fact that BM-MSCs are recruited to primary tumor sites was initially 
attributed to a role in maintenance and growth of the perivascular niche. However, 
soon after their description as part of the tumor microenvironment, research began 
on the interactions between BM-MSCs and CSCs. In 2007, Karnoub and colleagues 
first demonstrated the tumor-promoting capabilities of BM-MSCs on breast cancer 
stem cells.144 Researchers found that co-injection of BM-MSCs and breast cancer 
stem cells in mice resulted in increased invasion and metastasis. Interestingly, this 
phenomenon was linked to the secretion of chemokine cytokine ligand 5 (CCL5) by 
the BM-MSCs. CCL5 would then act via a paracrine mechanism to stimulate the 
motility of neighboring breast cancer stem cells.144 Subsequently, the tumor-
promoting properties of MSCs were described in other malignancies, such as colon 
and prostate cancer.145-148 Interestingly, the enhancement of tumors was not limited 
to the promotion of metastasis, but also included induction of immunosuppression 
and advancement of tumor growth.149-150 However, each of these studies utilized 
BM-MSCs in their investigations, and did not examine the tumor-promoting 
properties of native TA-MSCs isolated from the tumor microenvironment. 
Research accomplished by the Lang laboratory before I joined, investigated 
the interaction between GA-MSCs and GSCs.97 Results from this study were the first 
demonstration of GA-MSCs promoting the growth and aggressive nature of gliomas. 
In vitro co-culture experiments showed that GA-MSCs increased the proliferation 
and clonogenicity of GSCs, when compared to untreated controls (Figure 13). 
Additionally, the co-implantation of GA-MSCs and GSC into the flanks of mice 
resulted in a decrease in median survival (Figure 14). Furthermore, tumor burden 
was significantly increased with co-implantation of GA-MSCs and GSCs into the 
flanks of mice (Figure 15). These glioma-promoting properties were linked to the 
secretion of interleukin-6 (IL-6) by GA-MSCs into the extracellular space and 
subsequent utilization by neighboring GSCs (Figure 16). Lastly, the IL-6 mediated 
tumor-promoting effects were found to be the result of downstream activation of the 
JAK/STAT3 pathway in GSCs. (Figure 17).97 
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Figure 13. GA-MSCs promote the 
growth and self-renewal of GSCs. (A) 
Proliferation assay for 3 GSC lines 
demonstrating significant increases in 
viability after culturing in conditioned 
medium derived from BM-MSC and 2 
GA-MSC lines. (B) Clonogenic assay for 
3 GSC lines demonstrating a significant 
increase in neurosphere formation after 
culturing in conditioned medium derived 
from BM-MSC and GA-MSC.
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Figure 14. GA-MSCs decrease median 
survival in mice with GSC xenografts. 
Survival curve for GSC 7-2 demonstrating a 
significant decrease in median survival after 
co-injection with BM-MSC and GA-MSC 230.
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Figure 15. GA-MSCs increase tumor burden in 
mice with GSC xenografts. Flank tumors for mice 
with GSC 7-2 xenografts demonstrating an increase 
in tumor burden after co-injection with BM-MSC and 
GA-MSC 230.
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Figure 16. GA-MSCs secrete growth 
promoting cytokines. (A) Cytokine array 
immuno-blot demonstrating the secretion 
several cytokines by BM-MSC and GA-MSC 
230. (B) Proliferation assay for GSCs 
demonstrating a significant increase in viability  
after treatment with IL-6.
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Figure 17. IL-6 secretion from GA-MSCs activates STAT3. (A) Western blot 
analysis for GSC demonstrating increased p-STAT3 expression after co-culture 
with BM-MSC and GA-MSC 230. (B) Proliferation assay for GSC demonstrating 
significant dose dependent decreases in viability after treatment  GA-MSC and 
STAT3 inhibitor (WP1066). (C) Proliferation assay for GSC demonstrating dose 
dependent decreases in neurosphere formation after treatment with GA-MSC 
and STAT3 inhibitor (WP1066).
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The findings from studies investigating the role of MSCs in gliomas, and thus 
the intercellular communication between MSCs and GSCs, is limited to the 
description of soluble tumor-promoting proteins by MSCs. However, one key 
component of paracrine intercellular interactions that has been overlooked is that of 
exosome communication. Although the physiologic and pathologic release of 
exosomes has recently been investigated in a variety of disease processes, 
including cancer, the function of exosomes secreted from non-cancerous cells within 
the tumor niche has never been explored.151 This research disparity, combined with 
the extensive evidence describing the various contents of exosomes, highlights a 
gap in knowledge as to the function of MSC-derived exosomes. Thus, further 
examination is necessary to evaluate this novel intercellular exosomal 
communication pathway between MSCs and GSCs. 
 Currently, there are only two reports investigating the role of tumor stroma-
derived exosomes within the microenvironment. In 2013, Luga, et al., found that 
exosomes released from cancer associated fibroblasts (CAFs) in breast cancer, 
increased the invasion and motility of breast cancer cells.152 This effects was linked 
to the activation of the Wnt-planar cell polarity (Wnt-PCP) signaling pathway, via 
Wnt11 molecules packaged in CAF-derived exosomes. Luga and colleagues 
concluded that this intercellular communication system led to enhanced metastatic 
capabilities of breast cancer.152 This is the first study demonstrating the tumor-
promoting capabilities of exosomes derived from stromal cells isolated from the 
tumor microenvironment. Recently, in 2014, Wang and colleagues, demonstrated 
that exosomes from gastric carcinoma-mesenchymal stem cells (GC-MSCs) were 
capable of increasing the growth and migration of human gastric carcinoma (HGC) 
cells.153 These effects were found to be mediated by the delivery of miR-221 to HGC 
cells by GC-MSC-derived exosomes. The onco-miRNA miR-221 is linked to the 
down-regulation of certain cyclin dependent kinase inhibitors and anti-apoptotic 
factors.153 Together these two studies demonstrate the tumor-promoting role of 
stroma-derived exosomes, and define a mechanism by which the exosomal contents 
can mediate the tumor-enhancing effects.   
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Another study published by Roccaro, et al., showed the tumor-promoting 
properties of BM-MSC-derived exosomes in multiple myeloma (MM), albeit using 
cells that were not part of the microenvironment in the primary tumor.154 Here 
researchers found that MSCs harvested from the bone marrow (BM-MSCs) of 
patients with MM, had different genetic and proteomic profiles than BM-MSCs 
harvested from normal subjects. These differences carried over to differences in the 
genetic and proteomic profiles of exosomes derived from both BM-MSC lines. 
Roccaro and colleagues found that BM-MSC-derived exosomes from MM patients 
had higher levels of levels of oncogenic proteins, cytokines and adhesion molecules, 
when compared to BM-MSC-derived exosomes from normal subjects. These tumor 
promoting proteins were shown to transfer to plasma cells in both in vitro and in vivo 
mouse models.154 Importantly, the BM-MSCs of MM patients were harvested from 
abnormal bone marrow, not primary tumor sites, and therefore not associated with 
the microenvironment. However, MM is thought to arise from abnormal bone 
marrow, and these abnormal BM-MSCs may play a role in the initial malignant 
transformation of plasma cells in MM.154 Nevertheless, this study demonstrates the 
tumor-promoting capabilities of exosomes derived from BM-MSCs, which can be 
recruited to, and engrafted in, gliomas. 
In 2011, Zhu, et al., investigated the tumor promoting effects of BM-MSC-
derived exosomes on human gastric carcinoma and colon cancer cell lines.155 They 
found that tumor stem cells treated with BM-MSC-derived exosomes had increased 
proliferation in vitro, and promoted tumorigenicity in in vivo mouse xenografts. 
Additionally, they showed that these results were due to the increased expression of 
vascular endothelial growth factor (VEGF) in the cancer stem cells, via exosomal 
activation of extracellular signal-regulated kinase 1/2 (ERK1/2).155 Their findings 
suggested a novel mechanism by which intercellular communication could take 
place within a tumor. 
Although the Roccaro and Zhu articles demonstrate the tumor promoting 
properties of BM-MSC-derived exosomes, these cells are not the most accurate 
representation of MSCs in the tumor microenvironment. Once recruited and 
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entrenched in the tumor niche, BM-MSCs are influenced by neighboring CSCs and 
undergo specific changes that alter their biology.156-161 Although they still exhibit the 
classical MSC morphology, surface markers, and tri-differentiation capabilities, TA-
MSCs differ from normal BM-MSCs in proliferation rate and genetic signature.97 
Therefore the efficacy of these studies could be improved by investigating the effects 
of TA-MSC-derived exosomes on the progression of malignancy. Thus, the focus of 
my thesis is the investigation of exosomal communication within the glioma 
microenvironment, utilizing GA-MSCs and GSCs isolated from patient tumor. 
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1.6 Conclusions 
 In this chapter I described that exosomes are 40-100nm in diameter with a 
lipid bilayer, are formed and packaged intracellularly within the endosomal system, 
and are secreted from the cell via exocytosis. I discussed how exosomes are 
different from other larger microvesicles, in formation, content and morphology. I 
described the specific protein constituents of the exosomal membrane, the cellular 
elements that have been found in the intra-exosomal compartment, and how 
exosomes interact with recipient cells via fusion or endocytosis. I explored the 
studies evaluating exosomes in gliomas, from the transfer of an oncogenic protein 
receptor, to diagnostic properties in the serum, to new therapeutic strategies. I 
described the constituents of the glioma microenvironment, and how it is nurturing to 
resident GSCs. I discussed how we isolated GA-MSCs from glioma surgical 
specimens, and that GA-MSC-mediate promotion of tumor growth is link to cytokine 
secretion. I described how MSC-derived exosomes promote malignant growth in 
other tumor types, but have not been studied in gliomas. Based on this background, 
investigating the effects of GA-MSC-derived exosomes on GSCs will provide a 
better model to study the role of stroma-derived exosomes in the glioma 
microenvironment. 
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1.7 Hypothesis 
 Given the capability of exosomes to participate in paracrine communication 
between cells, and also the potential of exosome content to alter the biology of 
recipient cells, I hypothesized that GA-MSC-derived exosomes increase the growth 
and evolution of gliomas via the delivery of specific miRNA to recipient GSCs. To 
test this hypothesis I investigated three specific aims: 
1. I hypothesized that GA-MSCs produce exosomes with unique proteomic and 
genomic profiles when compared with parental GA-MSCs. To test this 
hypothesis, I propose to: 
a. Demonstrate that GA-MSCs produce exosomes. 
b. Characterize the production system of GA-MSC-derived exosomes. 
c. Characterize the content of GA-MSC-derived exosomes. 
2. I hypothesized that GA-MSC-derived exosomes can be internalized by GSCs 
and can increase the tumorigenicity of GSCs. To test this hypothesis, I 
propose to: 
a. Demonstrate that GSCs can internalize GA-MSC-derived exosomes. 
b. Show that GA-MSC-derived exosomes increase the proliferation and 
clonogenicity of GSCs in vitro. 
c. Establish that GA-MSC-derived exosomes increase the tumorigenicity 
of GSCs in vivo. 
3. I hypothesized that MicroRNAs delivered via GA-MSC-derived exosomes 
increase the tumorigenicity of GSCs. To test this hypothesis, I propose to: 
a. Identify miRNA in GA-MSC-derived exosomes that could potentially 
influence the growth of GSCs. 
b. Demonstrate that specific miRNA in GA-MSC-derived exosomes 
increase the proliferation and clonogenicity of GSCs in vitro. 
c. Establish that specific miRNA in GA-MSC-derived exosomes increase 
the tumorigenicity of GSCs in vivo. 
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Chapter II 
Isolation and Characterization of 
GA-MSC-Derived Exosomes 
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Isolation and Characterization of GA-MSC-Derived Exosomes 
 
 Understanding the role of exosomes in the communication between GA-
MSCs and GSCs requires evidence that GA-MSCs release exosomes, and that 
these GA-MSC-derived exosomes contain elements that can alter the biology of 
GSCs. To my knowledge there is little information about the production of exosomes 
by GA-MSCs and detailing of the content of GA-MSC-derived exosomes has never 
been performed. Therefore, I hypothesized that GA-MSCs produce exosomes with 
unique proteomic and genomic profiles when compared with parental GA-MSCs. To 
test this hypothesis, I first show that GA-MSCs produce nano-vesicles that qualified 
as exosomes. These results proved that this tumor stroma constituent is capable of 
exosome production. I then determined the extent to which external cellular 
stressors affected production of GA-MSC-derived exosomes. These experiments 
showed that exosomes are released under conditions that simulate the tumor niche. 
Finally, I characterized the content of GA-MSC-derived exosomes; specifically, I 
interrogated the protein and miRNA profiles. These experiments identified exosomal 
miRNAs that have the potential to alter the biology of GSCs. 
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2.1 Experimental Methods 
To investigate the role of exosomes in the communication pathway between 
GA-MSC and GSCs, I utilized commercially available human BM-MSCs (Lonza, Inc.) 
and also GA-MSCs isolated from human glioma surgical specimens. GA-MSCs were 
isolated from the surgical specimens by applying the same methods used to isolate 
human BM-MSCs.143 I selected four GA-MSCs lines that spanned the range of 
glioma grades (Table 1), in order to assess for any exosomal differences among 
degree of tumor pathology. All four GA-MSC lines met the criteria for MSCs as 
outlined by the International Society for Cellular Therapy (ISCT).118 Specifically, all 
GA-MSC lines have spindle shape morphology and are adherent in culture. 
Additionally, all GA-MSC lines expressed the mesenchymal surface markers CD73, 
CD90 and CD105, and did not express the endothelial surface marker CD34, the 
hematopoietic surface marker CD45, or the neural stem cell marker CD133. Finally, 
all GA-MSC lines possessed the ability to tri-differentiate into adipocytes, 
chondrocytes and osteocytes.118 
I also chose four GSC lines which were isolated from human glioma surgical 
specimens using the methods described by Singh, et al. (Table 2).86 Importantly, two 
of these GSCs (GSC-20 and GSC-262) were isolated from the same tumor 
specimens from which were isolated two of the GA-MSC lines (GA-MSC-262 and 
GA-MSC-20). This provided us with two matching GA-MSC/GSC pairs. Importantly, 
the GA-MSCs are unique from the corresponding GSCs. GA-MSCs do not express 
the same genetic aberrations as GSCs, nor do they form tumors in mouse 
xenografts as do GSCs.97 Interestingly, GA-MSCs also differ from normal human 
BM-MSC in both genetic and growth profiles.97     
Isolation of GA-MSC-Derived Exosomes 
In order to isolate MSC-derived exosomes, BM-MSCs and GA-MSCs were 
expanded to approximately 106 cells in MSC growth medium: Eagle’s Minimum 
Essential Medium Alpha (Sigma-Aldrich), 10% fetal bovine serum, 1% penicillin-
streptomycin,  and  1%  glutamine.  GA-MSCs  were  then  washed  and  allowed  to   
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Table 2. GSCs exhibit CSC-like characteristics. GSC 
lines express the CD133 neural stem cell marker, do not 
express the CD73, CD90 and CD105 mesenchymal 
markers, and are tumorigenic in mice (G = growth). 
Cell Line Pathology % CD73/90/105 % CD133
In Vivo 
Growth
GSC 11 Grade IV 4.0 59.0 G
GSC 7-2 Grade IV 2.9 75.0 G
GSC 262* Grade IV 6.4 28.6 G
GSC 20* Grade IV 4.0 26.0 G
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incubate for 48 hours in serum-free NSC medium: Dulbecco’s Modification of 
Eagle’s Medium/Ham’s F-12 50/50 mix with L-Glutamine (Corning CellGro), 2% B-27 
supplement (Gibco), and 1% penicillin-streptomycin.  
 BM-MSC-derived and GA-MSC-derived exosomes were then isolated by 
differential ultracentrifugation, as described by Thery, et al.162 Briefly, MSC-derived 
conditioned medium was collected and passed through a 22μm filter to remove dead 
cells and cellular debris, and centrifuged at 10,000 x gravity for 30 minutes, to 
remove large microvesicles (non-exosomal). The supernatant was collected and 
ultra-centrifuged at 100,000 x gravity for 90 minutes. The supernatant (exosome-free 
conditioned medium) was removed yielding a raw exosome pellet, which was 
resuspended in PBS. Exosomes were further purified by another ultra-centrifugation 
at 100,000 x gravity, for 90 minutes, with or without a 30% sucrose cushion 
depending on the experimental usage. Exosome pellets were then resuspended in 
PBS, NSC medium or lysis buffer depending on the experimental need. 
Western Blot Analysis of GA-MSC-Derived Exosomes 
 In order to confirm that nano-vesicles isolated from MSC-derived conditioned 
medium were exosomes, I performed western blot for known exosomal markers. 
BM-MSC-derived and GA-MSC-derived exosomes were isolated by differential 
ultracentrifugation. Protein from BM-MSC-derived and GA-MSC-derived exosomes 
was extracted using membrane lysis buffer, and measured by Bradford protein 
assay. Western blot for the exosomal surface markers CD63 and GAPDH on MSC-
derived exosomes, and the corresponding parental cell, were performed using anti-
CD63 (Santa Cruz Biotechnology, Inc.) and anti-GAPDH (Sigma-Aldrich). 
Additionally, western blot for the non-exosomal surface markers CD16 and CD32 on 
MSC-derived exosomes, and the corresponding parental cell, were performed using 
anti-CD16 (Abcam) and anti-CD32 (Abcam).   
Electron Microscopic Analysis of GA-MSC-Derived Exosomes 
 In order to more clearly confirm that nano-vesicles isolated from MSC-derived 
conditioned medium were exosomes, I performed electron microscopy analysis to 
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visualize morphology. BM-MSC-derived and GA-MSC-derived exosomes were 
isolated by differential ultracentrifugation. BM-MSC-derived and GM-MSC-derived 
exosomes were prepared for analysis by electron microscopy (EM) by the accepted 
protocol published by Thery, et al.162 Briefly, MSC-derived exosomes were affixed to 
Formvar coated EM grids using 2% paraformaldehyde (PFA), and contrasted with 
4% uranyl-oxalate. MSC-derived exosomes were then examined by electron 
microscopy on a JEM 1010 transmission electron microscope (JEOL) at an 
accelerating voltage of 80 Kv. Digital images were obtained using the AMT Imaging 
System (Advanced Microscopy Techniques). For gold particle (10nm) labeling, 
exosome grids were subjected to immuno-gold staining of the exosomal surface 
marker CD63 and the non-exosomal markers CD16 and CD32, utilizing gold-anti-
rabbit (Sigma Aldrich), anti-CD63 (Santa Cruz Biotechnology, Inc.), anti-CD16 
(Abcam), and anti-CD32 (Abcam). MSC-derived exosomes were then examined by 
electron microscopy as previously described. 
Characterization of the Production System for GA-MSC-Derived Exosomes 
In order to characterize the production system of MSC-derived exosomes, I 
utilized various growth conditions and quantified exosomes by ELISA. BM-MSCs 
and four GA-MSCs were expanded to 50%, 60%, 70%, 80%, 90% and 100% 
confluency, in eight 15cm dishes. Two of the dishes were incubated for 24 hours, 
two incubated for 48 hours, two incubated for 72 hours and two incubated for 96 
hours. BM-MSC-derived and GA-MSC-derived exosomes were then isolated by 
differential ultracentrifugation as previously described. BM-MSC-derived and GA-
MSC-derived exosomes from each time point in each group, were quantified by 
CD63 ELISA (System Biosciences), which utilizes standards calibrated by 
NanoSight. Briefly, BM-MSC-derived and GA-MSC-derived exosomes were affixed 
to anti-CD63 coated 96-well plates overnight, and subsequently analyzed after the 
addition of a secondary antibody, followed by an enzymatic colorimetric substrate. 
Later experiments utilized the NanoSight (NS300) system to not only quantify, but 
also measure the diameter of isolated exosomes. Briefly, BM-MSC-derived and GA-
MSC-derived exosomes were resuspended in PBS, diluted 1:100, and passed 
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through the laser detector of the NS300. The NS300 utilizes laser light scattering to 
visualize the Brownian motion of nano-sized particles. This technology not only 
enables the quantification exosomes, but also produces a size distribution which 
includes statistical parameters. 
Protein Characterization of GA-MSC-Derived Exosomes 
 In order to characterize the protein content of MSC-derived exosomes, I 
utilized protein array technology. BM-MSCs and GA-MSCs were expanded to 2.5 x 
107 cells in MSC medium, washed with PBS and cultured in NSC medium for 48 
hours. BM-MSC-derived and GA-MSC-derived conditioned medium (CM) was then 
collected, subjected to ultracentrifugation, the exosome-free conditioned medium 
(EF-CM) supernatant removed and saved, and the MSC-derived exosome pellets 
resuspended and lysed in neural stem cell (NSC) medium and lysis buffer. Immuno-
blot was then performed using human growth factor and cytokine antibody array kits 
(Bio Ray), on BM-MSC-derived and GA-MSC-derived CM, BM-MSC-derived and 
GA-MSC-derived EF-CM and BM-MSC-derived and GA-MSC-derived exosomes, as 
well as the NSC medium/lysis buffer control. Briefly, protein from exosome samples 
were affixed to anti-growth factor and anti-cytokine coated array plates overnight, 
and subsequently analyzed after the addition of a secondary antibody, followed by 
an enzymatic substrate.  
MicroRNA Characterization of GA-MSC-Derived Exosomes 
 In order to characterize the miRNA profile of MSC-derived exosomes, I 
utilized miRNA micro-array technology. BM-MSC-derived and GA-MSC-derived 
exosomes were isolated by differential ultracentrifugation, and exposed to RNase 
(1nM) for 15 minutes to eliminate free-floating extra-vesicular RNA elements. 
Remaining RNase was removed by PBS wash and subsequent centrifugation. Total 
RNA was then extracted by a combination of organic and solid-phase methods using 
the mirVana RNA isolation kit (Ambion). Additionally, total RNA was extracted from 
the parental cell line, and the miRNA profile for each sample was obtained using 
µParaflo® microfluidic biochip technology, through LC Sciences (Houston, TX). 
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2.2 Results 
Characterization of GA-MSC-Derived Exosomes 
One of the established methods for identifying exosomes is by western blot 
for tetraspanin membrane proteins and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), both of which are commonly associated with exosomes. Consequently, 
we cultured and isolated nano-vesicles from BM-MSCs and GA-MSCs (see 
experimental methods). Western blot results show the presence of CD63, a member 
of the tetraspanin family, as well as GAPDH in the protein extracted from isolated 
nano-vesicles from BM-MSC and GA-MSCs (Figure 18). Additionally, the non-
exosomal markers, CD16 and CD32, were absent in nano-vesicle isolates from BM-
MSC and GA-MSCs, although they were present in parental MSCs.163 These results 
indicate that the isolated MSC-derived nano-vesicles were exosomes. 
In addition to harboring specific membrane protein constituents, exosomes 
are also characterized by specific size and shape criteria as outlined by Thery, et 
al.162 However, the size of exosomes limits their visualization by conventional light 
microscopy, and electron microscopy (EM) is the gold standard for characterizing 
the morphology of exosomes. Therefore we used EM to further characterize the 
nano-vesicles isolated from BM-MSCs and GA-MSCs. EM of nano-vesicle isolates 
from BM-MSC and GA-MSCs demonstrate round nano-vesicles 40-100 nm in 
diameter, with a lipid bilayer, consistent with the known appearance of exosomes 
(Figure 19). To more precisely define these nano-vesicles as exosomes, we labeled 
the CD63 membrane protein with gold nano-particles. EM after immuno-gold 
staining against CD63, confirmed the presence of the tetraspanin exosomal marker 
in the membrane of these nano-vesicles. Furthermore, immuno-gold staining against 
CD16 and CD32 by EM, demonstrated the absence of these markers in the 
membrane of these nano-vesicles (Figure 20). These methods provided strong 
evidence that the nano-vesicles produced by BM-MSCs and GA-MSCs meet the 
criteria of exosomes. 
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Figure 18. MSC-derived nano-vesicles express exosomal markers. Analysis of 
the exosomal markers CD63 and GAPDH, as well as the non-exosomal markers 
CD32 and CD16, in exosomes derived from BM-MSC and four GA-MSC lines. 
CD63 is expressed in all MSC-derived exosomes, and expression is higher than in 
the parental cell. GAPDH is also expressed in all MSC-derived exosomes, however 
expression is higher in the parental cell. Both CD32 and CD16 are not expressed 
in all MSC-derived exosomes, but are expressed in the parental cell.  
 BM-MSC      GA-MSC     GA-MSC      GA-MSC       GA-MSC 
                          230             247              262                 20 
         Cell      +        -          +        -         +        -         +        -         +        - 
 Exosome      -        +          -        +         -        +         -        +         -        + 
CD63 
CD32 
CD16 
GAPDH 
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Figure 19. Morphology of MSC-derived nano-vesicles is identical to exosomes. 
Analysis of exosomes derived from BM-MSC and four GA-MSC lines, by scanning 
electron microscopy. Exosomes derived from all MSC lines exhibit the classical 
cupped-shape morphology with a distinct lipid bilayer, and are within the 40nm-100nm 
range. 
  BM-MSC         GA-MSC         GA-MSC         GA-MSC          GA-MSC 
                              230                  247                 262                   20 
500nm                    500nm                   500nm                   500nm                   500nm 
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Figure 20. Exosome marker is expressed on MSC-derived nano-vesicles. 
Immuno-gold labeling of the exosomal marker CD63, and non-exosomal markers 
CD32 and CD16, of exsomes derived from BM-MSC and four GA-MSC lines. (Top 
Panel) Gold anti-body can bind to and label CD63 expressed on the membrane of 
all MSC-derived exosomes. (Middle/Bottom Panels) Gold anti-body cannot 
recognize any CD32 or CD16 markers in all MSC-derived exosomes.  
     BM-MSC        GA-MSC         GA-MSC         GA-MSC          GA-MSC 
                                230                  247                 262                   20 
CD63 
 
 
 
 
 
 
 
CD32 
 
 
 
 
 
 
 
CD16 
100nm                      100nm                      100nm                      100nm                      100nm  
100nm                      100nm                      100nm                     100nm                      100nm  
100nm                      100nm                      100nm                      100nm                      100nm  
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The size of BM-MSC-derived and GA-MSC-derived exosomes was further 
verified by utilizing NanoSight technology, which can determine both the diameter 
and number of exosomes. Results from NanoSight analysis show the size 
distribution of BM-MSC-derived and GA-MSC-derived exosomes to be within the 
established 40-100nm range for exosomes (Figure 21). Interestingly, the average 
diameter of exosomes derived from BM-MSCs and GA-MSCs were not significantly 
different (p > 0.05, student’s t-test). These data correlated with results of the western 
blot and electron microscopy analysis, and further supported the classification of the 
isolated BM-MSC-derived and GA-MSC-derived nano-vesicles as exosomes.    
Production of GA-MSC-Derived Exosomes Under Cellular Stress 
 In order to understand the influence of culture conditions on exosomal 
production, we plated BM-MSCs and GA-MSCs at varying confluency and isolated 
exosomes at different time points (see experimental methods). These experiments 
aimed to mimic the tumor microenvironment by increasing the cell culture time, 
leading to decreased nutrients, as well as culturing cells at increasing levels of 
confluency, leading to more cell-to-cell contact. Under these conditions, BM-MSC 
and GA-MSCs initially increase their exosome production rate as nutrients are being 
used and cell-to-cell contact increases (Figure 22). However after 48 hours culture 
time and 70-80% confluency, BM-MSC-derived and GA-MSC-derived exosome 
production begins to decline. These results indicate that both BM-MSCs and GA-
MSCs respond to cellular stress by decreasing exosome production, most likely for 
conservation of energy. 
Growth Factor Content of GA-MSC-Derived Exosomes 
 GA-MSC-derived exosomes may alter the growth of GSCs via delivery of 
growth factors that can activate receptors on the recipient cell, or by transfer of 
growth factor receptors that are then incorporated into the membrane of the recipient 
cell. Therefore, I utilized protein array technology to analyze 33 growth factors and   
8 growth factor receptors in BM-MSC-derived and GA-MSC-derived exosomes 
(Table 3).  Specifically,  BM-MSCs  and  GA-MSCs  were  cultured  and  protein was  
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D. GA-MSC 262          E. GA-MSC 20 
                                     Figure 21. MSC-derived nano-vesicles exhibit exosome size 
distribution. (A) BM-MSC-derived exosomes have a mean diameter of 
95nm. (B) GA-MSC 230-derived exosomes have a mean diameter of 94nm. 
(C) GA-MSC 247-derived exosomes have a mean diameter of 74nm. (D) GA-
MSC 262 derived exosomes have a mean diameter of 95nm. (E) GA-MSC 
262-derived exosomes have a mean diameter of 83nm.   
A. BM-MSC                 B. GA-MSC 230            C. GA-MSC 247 
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Figure 22. MSC-derived exosomes exhibit specific production 
systems. (A) Exosome production system for BM-MSC 
demonstrating a maximum of 7.87 x 10
9
 exosomes produced at 
80% confluency and 72 hours in culture. 
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Figure 22. MSC-derived exosomes exhibit specific production 
systems. (B) Exosome production system of GA-MSC 230 
demonstrating a maximum of 7.39 x 10
9
 exosomes produced at 
70% confluency and 72 hours in culture. (C) Exosome production 
system of GA-MSC 247 demonstrating a maximum of 7.57 x 10
9
 
exosomes produced at 80% confluency and 72 hours in culture.  
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Figure 22. MSC-derived exosomes exhibit specific production 
systems. (D) Exosome production system of GA-MSC 262 
demonstrating a maximum of 8.03 x 10
9
 exosomes produced at 
70% confluency and 48 hours in culture. (C) Exosome production 
system of GA-MSC 247 demonstrating a maximum of 8.51 x 10
9
 
exosomes produced at 70% confluency and 48 hours in culture.  
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extracted from isolated exosomes and analyzed by immune-blot (see experimental 
methods). As controls, I utilized BM-MSC-derived and GA-MSC-derived conditioned 
medium (CM), BM-MSC-derived and GA-MSC-derived exosome-free conditioned 
medium (EF-CM), and neural stem cell (NSC) medium alone (Figure 23). GA-MSC-
derived exosomes had the same growth factor profile as the neural stem cell 
medium alone, with the presence of four growth factors: granulocyte colony 
stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-
CSF), insulin-like growth factor-2 (IGF-II), and transforming growth factor-β (TGF- β). 
These data indicate that GA-MSC-derived exosomes did not contain any of the 
growth factors or growth factor receptors analyzed by the protein array. In contrast, 
several growth factors, such as platelet-derived growth factor-AA (PDGF-AA), 
insulin-like growth factor binding-protein-2 (IGFBP-2), and vascular endothelial 
growth factor (VEGF), are present in GA-MSC-derived CM (which contains a low 
concentration of exosomes), and matches the profile seen in the GA-MSC-derived 
EF-CM after ultra-centrifuge extraction of exosomes. Therefore, removing exosomes 
from GA-MSC-derived CM does not eliminate or decrease growth factor signatures. 
These data indicate that, whereas GA-MSC-derived CM and EF-CM contain soluble 
growth factors secreted by the cell, these growth factors and growth factors 
receptors are not present within BM-MSC-derived and GA-MSC-derived exosomes.  
Profiling of Cytokines in GA-MSC-Derived Exosomes 
GA-MSC-derived exosomes may also affect GSCs by delivering cytokines. 
Therefore, I utilized protein array technology to analyze 59 cytokines and 1 cytokine 
receptor in BM-MSC-derived and GA-MSC-derived exosomes (Table 4). 
Specifically, BM-MSCs and GA-MSCs were cultured and protein was extracted from 
isolated exosomes and analyzed by immune-blot (see experimental methods). As 
controls, I utilized BM-MSC-derived and GA-MSC-derived conditioned medium 
(CM), BM-MSC-derived and GA-MSC-derived exosome-free conditioned medium 
(EF-CM), and neural stem cell (NSC) medium alone (Figure 24). The cytokine 
protein arrays for BM-MSC-derived and GA-MSC-derived exosomes demonstrate no 
cytokines, which matches the profile seen for NSC medium alone. In contrast, BM- 
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Figure 23. MSC-derived exosomes do not contain growth factors. 
Profiling of  33 growth factors and 8 growth factor receptors in exosomes 
derived from BM-MSC and four GA-MSC lines. The growth factor profiles for 
MSC-derived conditioned mediums and exosome-free conditioned mediums 
are identical, and demonstrate the expression of numerous growth factors. 
The growth factor profiles for MSC-derived exosomes is identical to the lysis 
buffer plus resuspension medium (control), and do not demonstrate the 
expression of any growth factors or growth factor receptors.   
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Figure 24. MSC-derived exosomes do not contain cytokines. Profiling of  59 
cytokines and 1 cytokine receptor in exosomes derived from BM-MSC and four 
GA-MSC lines. The cytokine profiles for MSC-derived conditioned mediums and 
exosome-free conditioned mediums are identical, and demonstrate the 
expression of several cytokine. The cytokine profiles for MSC-derived exosomes 
is identical to the lysis buffer plus resuspension medium (control), and do not 
demonstrate the expression of any cytokine or cytokine receptors.   
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MSC-derived and GA-MSC-derived CM (which contains a low concentration of 
exosomes), contained several cytokines, such as interleukin-6 (IL-6) and monocyte 
chemo-attractant protein-1 (MCP-1), and has a similar profile as BM-MSC-derived 
and GA-MSC-derived EF-CM after ultra-centrifuge extraction of exosomes. 
Therefore, removing exosomes from BM-MSC-derived and GA-MSC-derived CM 
does not alter the cytokine signatures, indicating that these cytokines are not present 
within GA-MSC-derived exosomes.  
MicroRNA Profiling of GA-MSC-Derived Exosomes 
 Exosomes are known to contain miRNA which, if present in GA-MSC-derived 
exosomes, have the potential to alter GSC growth by regulating genes at the level of 
transcription. Therefore, I utilized miRNA micro-array technology to analyze 2,019 
miRNAs (miRBase 19.0) for their level of expression in GA-MSC-derived exosomes. 
Specifically, BM-MSCs and GA-MSCs were cultured and total RNA was extracted 
from isolated exosomes, as well as from the parental cell (see experimental 
methods). The resulting miRNA profiles for GA-MSC-derived exosomes demonstrate 
the presence of numerous miRNAs, distinctly different from that of the parental cell 
line with p-values < 0.001 by paired student’s t-test (Figure 25). Interestingly, the 
miRNA profiles for GA-MSC-derived exosomes were significantly different from each 
other (p <0.001, one-way analysis of variance) (Figure 26). However, when 
analyzed individually, the miRNA profiles between BM-MSC-derived exosomes and 
GA-MSC-247-derived exosomes, as well as between GA-MSC-230-derived 
exosomes and GA-MSC-247-derived exosomes, were not significantly different from 
each other (p > 0.05, student’s t-test). Further analysis identified 37 miRNAs with an 
average expression level of ≥ 5000 hybridization intensity (top 0.1%), among all 
MSC-derived exosomes (Table 5), and were termed highly expressed miRNA. 
Although the overall miRNA profiles were significantly different among the group of 
MSC-derived exosomes, these highly expressed miRNA were consistent throughout 
the group. This indicates that the presence of these specific miRNAs may be 
conserved in all MSC-derived exosomes, and that any effects on GSC growth may 
be linked to these highly expressed miRNAs.  
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Figure 25. MSC-derived exosomes contain miRNA. (A/B) Profiling of 
2,109 miRNA (miRBase 19.0) in BM-MSC and BM-MSC-derived exosomes. 
BM-MSC-derived exosomes  expressed a significantly different miRNA profile 
compared to parental BM-MSC (p < 0.001, paired student’s t-test). 
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GA-MSC 230 Exosome miRNA Profile 
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GA-MSC 230 miRNA Profile 
Figure 25. MSC-derived exosomes contain miRNA. (C/D) Profiling of 
2,109 miRNA (miRBase 19.0) in GA-MSC 230 and GA-MSC 230-derived 
exosomes. GA-MSC 230-derived exosomes  expressed a significantly 
different miRNA profile compared to parental GA-MSC  230 (p < 0.001, 
paired student’s t-test). 
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GA-MSC 247 Exosome miRNA Profile 
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GA-MSC 247 miRNA Profile 
Figure 25. MSC-derived exosomes contain miRNA. (E/F) Profiling of 
2,109 miRNA (miRBase 19.0) in GA-MSC 247 and GA-MSC 247-derived 
exosomes. GA-MSC 247-derived exosomes  expressed a significantly 
different miRNA profile compared to parental GA-MSC  247 (p < 0.001, 
paired student’s t-test). 
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GA-MSC 262 Exosome miRNA Profile 
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GA-MSC 262 miRNA Profile 
Figure 25. MSC-derived exosomes contain miRNA. (G/H) Profiling of 
2,109 miRNA (miRBase 19.0) in GA-MSC 262 and GA-MSC 262-derived 
exosomes. GA-MSC 262-derived exosomes  expressed a significantly 
different miRNA profile compared to parental GA-MSC  262 (p < 0.001, 
paired student’s t-test). 
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GA-MSC 20 Exosome miRNA Profile 
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GA-MSC 20 miRNA Profile 
Figure 25. MSC-derived exosomes contain miRNA. (I/J) Profiling of 2,109 
miRNA (miRBase 19.0) in GA-MSC 20 and GA-MSC 20-derived exosomes. 
GA-MSC 20-derived exosomes  expressed a significantly different miRNA 
profile compared to parental GA-MSC  20 (p < 0.001, paired student’s t-
test). 
I 
J 
71 
 
  
-200
-150
-100
-50
0
50
100
150
200
-200 -150 -100 -50 0 50 100 150 200
Δ
 C
h
a
n
g
e
 i
n
 E
x
p
re
s
s
io
n
 
Δ Hybridization Intensity 
GA-MSC 262 
GA-MSC 20 
BM-MSC 
GA-MSC 230 
GA-MSC 247 
Figure 26. MicroRNA profiles of MSC-derived exosomes are different. 
Graphical representation of the difference in miRNA expression, between 
individual MSC-derived exosomes and the average miRNA expression for the 
group, versus the difference in change expression of miRNA (between the 
parental cell and exosome), between individual MSC-derived exosomes and 
the average fold change for the group. The change in miRNA profile standard 
deviation, between individual MSC-derived exosomes and the standard 
deviation for the group, is denoted by sphere size. MicroRNA profiles for the 
group of MSC-derived exosomes were significantly different from each other (p 
< 0.01, ANOVA). Individual comparison of miRNA profiles between BM-MSC-
derived exosomes and GA-MSC 247-derived exosomes, as well as between 
GA-MSC 230-derived exosomes and GA-MSC 247-derived exosomes, were 
not significantly different from each other (p > 0.05, student’s t-test). 
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Table 5. MSC-derived exosomes contain highly expressed miRNA. MSC-
derived exosomes contain 37 miRNA with average expression levels greater 
than 5000 hybridization intensity (> 3.0 standard deviations from the mean). 
Highly Expressed 
miRNA
Mean 
Expression 
Level
SD Above 
the Mean
hsa-miR-21-5p 26,723 17.98
hsa-miR-3960 19,651 13.16
hsa-miR-3665 16,364 10.92
hsa-miR-6089 16,163 10.79
hsa-miR-6087 15,568 10.38
hsa-miR-6090 12,200 8.08
hsa-miR-1246 11,941 7.91
hsa-miR-4497 10,837 7.16
hsa-miR-4668-5p 10,819 7.14
hsa-miR-4508 10,268 6.77
hsa-miR-6125 9,926 6.53
hsa-miR-1234-5p 9,568 6.29
hsa-miR-574-5p 9,568 6.29
hsa-let-7a-5p 9,482 6.23
hsa-miR-23a-3p 9,045 5.93
hsa-miR-4530 8,426 5.51
hsa-miR-4516 8,252 5.39
hsa-miR-23b-3p 8,244 5.39
hsa-miR-3613-3p 8,223 5.37
hsa-miR-4505 7,911 5.16
hsa-miR-574-3p 7,882 5.14
hsa-let-7c 7,793 5.08
hsa-miR-4787-5p 7,561 4.92
hsa-miR-638 7,482 4.87
hsa-let-7d-5p 7,272 4.73
hsa-miR-3656 7,110 4.62
hsa-let-7f-5p 7,008 4.55
hsa-miR-125b-5p 6,383 4.12
hsa-miR-3620-5p 6,373 4.11
hsa-let-7b-5p 6,046 3.89
hsa-miR-4492 5,726 3.67
hsa-miR-4507 5,398 3.45
hsa-miR-100-5p 5,282 3.37
hsa-miR-1587 5,269 3.36
hsa-miR-4484 5,069 3.22
hsa-miR-6085 5,046 3.21
hsa-miR-494 5,043 3.21
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2.3 Discussion 
 In this chapter I show that GA-MSCs release exosomes, and that the 
production rate is dependent on both time in culture and cell-to-cell contact. I also 
show that the BM-MSC-derived and GA-MSC-derived exosomes do not contain 
significant amounts of growth factors or cytokines, but they do contain significant 
amounts of miRNA, including a specific group of miRNA that is highly expressed. 
 MSC-derived exosomes have been confirmed by the use of both surface 
markers, such as the tetraspanin proteins CD9 and CD81, as well as by electron 
microscopy.32-33,164 A review of the most cited exosomal surface markers was 
published by Mathivana, et al., and shows that the tetraspanin family proteins were 
reliable markers for the detection of exosomes, as was the glycolytic enzyme 
GAPDH.5 I show that GA-MSC-derived exosomes express both CD63 tetraspanin 
protein and GAPDH exosomal markers. Additionally, as in the seminal paper on 
exosome production by Trams, et al., I also visualized the characteristic morphology 
exhibited by GA-MSC-derived exosomes by electron microscopy. Most importantly, I 
was able to show by EM and immuno-gold staining that the CD63 surface marker 
was an integral part of the exosomal membrane.15 These multiple lines of evidence 
prove that GA-MSCs produce classical exosomes. 
 The rate at which exosomes are produced has, to this point, been assumed 
constant, although exogenous factors such as time in culture and cell-to-cell contact 
could have a significant impact. The effect of environmental factors such as hypoxia, 
oxidative stress, and physical contact has been shown to affect the secretome 
profile of secreted proteins of many cells types.165-167 Of these external factors, 
hypoxia has been the most extensively studied not only in secretomics, but also in 
the production of exosomes. For example, Ramteke, et al., demonstrated that 
exosomes secreted under hypoxic conditions by prostate cancer cells, enhance cell 
invasiveness and stemness, while Salomon, et al., showed that hypoxia-associated 
exosomes released from placenta-derived MSCs, mediate endothelial cell migration 
and blood vessel formation.168-169 Also, work by Park, et al., revealed that hypoxia 
induced squamous cell carcinoma cells to produce exosomes capable of enhancing 
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angiogenesis and metastasis, while King, et al., demonstrated that hypoxic 
conditions mediated an increase in exosome secretion by breast cancer cells, and 
that this effect was facilitated by HIF-1α.172-173 More relevant to my work, 
Kucharzewska, et al., showed that GBM-derived exosomes modified endothelial 
cells to improve tumor angiogenesis in a hypoxic environment.73 In addition to 
hypoxic stress, other cellular stressors have also been implicated in influencing 
exosome secretion. This can be seen in work by Hedlund, et al., in which thermal 
and oxidative stress in leukemic T-cells and B-cells produces enhanced 
immunosuppressive exosomes.174 These studies support the findings in which the 
controlled environmental factors, time in culture and cell-to-cell contact, affect the 
rate at which GA-MSC-derived exosomes are produced. To my knowledge this is the 
first evidence describing the effects of external stressors on exosome production 
rate, as the majority of research focuses on factors modifying exosomal content. 
Along this line, further investigation into the effects of other cellular stressors, along 
with paracrine signaling from neighboring GSCs, is necessary to gain a full 
understanding of GA-MSC-derived exosomes.   
 Exosomes have been shown to contain a variety of proteins, however, the 
use as a vehicle for delivering growth factors and cytokines is not well established. 
However, there is an association between exosomes and both growth factors and 
cytokines demonstrated in a variety of cell types. The content of exosomes can be 
altered by activation of growth factor receptors on the parental cell, as demonstrated 
by Genneback, et al., in which the treatment of cardiomyocytes with transforming 
growth factor-beta (TGF-β) and/or platelet derived growth factor-BB (PDGF-BB) 
resulted in cardiomyocyte-derived exosomes with significantly different mRNA 
content.173 Conversely, exosomes can affect the expression of certain growth factor 
and receptors in recipient cells, as shown by Lee, et al., in which BM-MSC-derived 
exosomes down-regulate expression of vascular endothelial factor (VEGF) in breast 
cancer cells.174 With respect to cytokines, Li and colleagues, show that stimulating 
liver non-parenchymal cells (LNPCs) with interferon-alpha (IFN-α) results in LNPC-
derived exosomes with increased anti-hepatitis B virus (HBV) molecules, and Bretz, 
et al., demonstrate that stimulation of monocytes with exosomes derived from 
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malignant breast cancer ascites, induces the expression of interleukins -1-beta (IL-
1β), -6 (IL-6), and tumor necrosis factor-alpha (TNF-α).175-176 Furthermore, Huang, et 
al., shows that dendritic cells-derived exosomes contain epidermal growth factor 
(EGFR) in their membrane, and Hawari, et al, demonstrates that vascular 
endothelial cell-derived exosomes harbor the tumor necrosis factor receptor (TNFR) 
in their lipid bilayer, indicating the exosomal transfer of functional growth factor and 
cytokine receptors.177-178 However, the packaging of these growth-promoting 
proteins inside exosomes, instead of in the exosomal membrane, has to my 
knowledge never been described. My results show the absence of a discrete set of 
growth factors and cytokines within the intra-exosomal compartment of GA-MSC-
derived exosomes, which is logical given that the receptors for these proteins are 
extracellular and signaling proteins would not be able to produce an effect while 
trapped inside an exosome. To date, the only growth factor related cellular elements 
found to be packaged in exosomes are mRNA for transforming growth fact-beta-1 
(TGF-β1) and insulin-like growth factor-1 (IGF-1) in endothelial cell-derived 
exosomes and BM-MSC-derived exosomes respectively, as described by Borges, et 
al., and Tomasoni, et al.179-180 This results however, does not preclude the idea that 
growth promoting proteins could be in the exosomal membranes. In fact, some 
groups genetically modify exosomes to express certain growth factors and cytokines 
on their surface to enable binding to the extracellular domain of receptors on the 
recipient cell, in order to produce a desired effect. For example, Yu, et al., modified 
dendritic cell-derived exosomes to express membrane bound transforming growth 
fact-beta-1 (TGF-β1), while Zhang, et al., modified renal cancer cell-derived 
exosomes to express membrane bound interleukin-12 (IL-12).181-182 The only known 
exosomal membrane proteins shown to produce growth promoting effects, are 
glycoproteins. Specifically, functional Wnt signaling proteins have been described in 
exosomes from both fibroblasts and BM-MSCs.152,183 These membrane bound 
proteins were not evaluated in my analysis of the classical and most well described 
growth factors and cytokines, and further investigation into their presence in GA-
MSC-derived exosomes is warranted. 
76 
 
 Genetic material, such as DNA and RNA, have been extensively described in 
the exosomes of many cell types. Therefore, it is reasonable that GA-MSC-derived 
exosomes contain unique miRNA profiles. In addition to growth factor mRNA being 
present in exosomes from endothelial and mesenchymal stem cells, other DNA and 
RNA species are now accepted as classical exosomal constituents. Waldenstrom, et 
al., found that cardiomyocyte-derived exosomes contain both DNA and RNA that 
were functional in recipient fibroblasts.184 However, DNA and RNA are general terms 
and include a variety of specific subtypes. In the realm of DNA species, Kahlert, et 
al., described the presence of double-stranded DNA, including mutations in KRAS 
and p53, in the exosomes derived from the serum of pancreatic cancer patients.185 
Additionally, the rare mitochondrial DNA (mtDNA) was discovered by Guescini, et 
al., in exosomes derived from myoblasts, astrocytes and GBM cells.70,186 With 
regards to RNA, the presence of non-coding RNA species, such as miRNAs, are 
more extensively described in exosomes than mRNA. MicroRNA has the potential to 
produce longer lasting effects in recipient cells due its slow decay rate and the ability 
to regulate multiple genes at the transcription level. In contrast mRNA influence is 
relatively brief due to its faster decay rate as a result of translation into a protein. 
Consistent with other cell types, I showed that the GA-MSC-derived exosomes 
contained unique miRNA profiles as compared to the parental cell, including a 
specific group of miRNA that were highly expressed. These results are further 
supported by Wang, et al., Chen, et al., Koh, et al., and Xin, et al., who all described 
a wide variety of both precursor and mature functional miRNA in exosomes derived 
from BM-MSCs.153,187-189 However, given the nature of mRNA and their potential as 
effectors on growth, the mRNA profiling of GA-MSC-derived exosomes is also 
necessary in future work. 
 One of the weaknesses in these experiments was not obtaining a full 
proteomic profile of GA-MSC-derived exosomes. Instead, I chose to focus on 
profiling 41 major growth factors and receptors, and 60 major cytokines and 
receptors. However, the list is not inclusive of all tumor-promoting proteins, and thus 
a full proteomic analysis would have improved the analysis. Likewise, I did not 
analyze the lipid component of GA-MSC-derived exosomes, which would be a more 
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complete characterization. Furthermore, I only characterized the miRNA within GA-
MSC-derived exosomes, and did not evaluate other DNA or RNA species. Indeed, 
mRNA could have a significant impact on recipient cells, when delivered via 
exosomes. However, I chose to focus on miRNA due to their broad range of targets 
and potential to alter gene expression at the level of transcription.  
 Conversely, one of the strengths of these experiments was the use of multiple 
modalities to detect exosomes. Not only did I demonstrate GA-MSC-derived 
exosome production by western blot, but I also confirmed production by electron 
microscopy, immuno-gold labeling, and ELISA. Another strength of these 
experiments was the characterization of GA-MSC-derived production under cellular 
stress. This evaluation more accurately mimics the tumor microenvironment. The 
last strength of the experiments was the full characterization of all known miRNAs. 
Although many of the miRNAs have yet to be studied, this profiling provided a better 
understanding of exosome content that is capable of altering gene expression.    
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2.4 Conclusions 
 The results outlined in this chapter demonstrate for the first time the 
production of exosomes by GA-MSCs. These GA-MSC-derived exosomes express 
the accepted CD63 and GAPDH markers, and lack CD16 and CD32 non-exosomal 
markers. Importantly, GA-MSC-derived exosomes are also within the established 
40-100nm range, and possess the characteristic lipid bilayer membrane. Moreover, 
the production of GA-MSC-derived exosomes varies with exposure to different levels 
of cellular stressors. Additionally, GA-MSC-derived exosomes do not contain 41 of 
the major growth factors, nor do they contain 60 of the major cytokines. However, 
GA-MSC-derived exosomes contain numerous miRNAs, with distinct profiles 
compared to the parental cell. Lastly, a specific group of miRNAs are highly 
expressed in all GA-MSC-derived exosomes. These results prove that GA-MSCs are 
capable of producing a varying amount of exosomes, depending on the 
environmental conditions, whose internal content have the potential to impact 
recipient cell biology. 
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GA-MSC-Derived Exosomes Increase GSC Tumorigenicity 
 
Proof that exosomes play a role in the communication between GA-MSCs 
and GSCs requires demonstrating that GA-MSC-derived exosomes are taken up by 
GSCs, and that these exosomes can modify the biology of GSCs. To my knowledge 
this analysis has never been conducted in gliomas. Investigating the exosomal 
interaction between cells of the tumor microenvironment may establish a new 
intratumoral paracrine communication mechanism. Therefore, I hypothesized that 
GA-MSC-derived exosomes can be internalized by GSCs and can increase the 
tumorigenicity of GSCs. To test this hypothesis, I first established that GSCs are 
capable of taking up GA-MSC-derived exosomes. These results proved that 
intercellular exosomal interaction is feasible. I then showed that GSC proliferation 
and clonogenicity is increased by GA-MSC-derived exosomes in vitro, and that GA-
MSC-derived exosomes increased the tumorigenicity of GSCs in vivo. These 
findings established that GA-MSCs in the glioma microenvironment can alter the 
growth and self-renewal of GSCs. Therefore, my studies indicate that GA-MSCs 
communicate with GSCs via exosomes. 
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3.1 Experimental Methods 
GSC Internalization of GA-MSC-Derived Exosomes 
 In order to fluorescently label and track GA-MSC-derived exosomes, GA-
MSCs were transduced with a commercially available GFP-CD63 lentiviral construct 
(System Biosciences), and expanded to 106 cells in MSC growth medium. 
Transduced GA-MSCs were then washed and incubated for 48 hours in serum-free 
NSC medium. GFP-labeled GA-MSC-derived exosomes were then isolated by 
differential ultracentrifugation (see Chapter 2 Experimental Methods), added to GSC 
cultures and allowed to incubate for 4 hours. Excess exosomes were subsequently 
removed by PBS wash, and effective internalization of GA-MSC-derived exosomes 
by GSCs was analyzed by fluorescent confocal microscopy. 
Effects of GA-MSC-Derived Exosomes on GSC Proliferation 
In order to isolate MSC-derived exosomes, BM-MSCs (Lonza, Inc.) and four 
GA-MSC lines (Table 1) were expanded to 5.0 x 107 cells in MSC growth medium. 
BM-MSCs and GA-MSCs were subsequently washed and incubated for 48 hours in 
serum-free NSC medium. Likewise, to isolate GSC-derived self-exosomes, four 
GSC lines (Table 2) were expanded to 1.0 x 107 cells in NSC growth medium. Both 
MSC-derived and GSC-derived exosomes were then isolated from the conditioned 
medium by differential ultracentrifugation and quantified by CD63 ELISA (see 
Chapter 2 Experimental Methods), The remaining supernatant after exosome 
extraction, exosome-free conditioned medium (EF-CM), was collected and utilized 
as a control. Additionally, neurospheres from four GSC lines (Table 2) were 
dissociated and placed in a 96 well plate at 2.5 x 103 cells/well. GSC-derived and 
MSC-derived exosomes were then added to GSC cultures at doses of 5.0 x 104 and 
1.0 x 105 exosomes/µL at time zero and at 48 hours, and incubated for a total period 
of 96 hours. GSCs were also treated with NSC medium and GA-MSC-derived EF-
CM. After 96 hours in culture, GSCs were assessed for viability using a colorimetric 
assay (water-soluble tetrazolium [WST-1], Roche), and the absorbance measured at 
450nm. Absorbance of GSCs treated with MSC-derived exosomes was compared to 
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that of untreated GSC controls. All experiments were performed in quadruplicate and 
statistical analysis was performed utilizing the paired student’s t-test. 
Effects of GA-MSC-Derived Exosomes on GSC Clonogenicity 
In order to isolate MSC-derived exosomes, BM-MSCs (Lonza, Inc.) and four 
GA-MSC lines (Table 1) were expanded to 5.0 x 107 cells in MSC growth medium. 
BM-MSCs and GA-MSCs were subsequently washed and incubated for 48 hours in 
serum-free NSC medium. Likewise, to isolate GSC-derived self-exosomes, four 
GSC lines (Table 2) were expanded to 1.0 x 107 cells in NSC growth medium. Both 
MSC-derived and GSC-derived exosomes were then isolated from the conditioned 
mediums by differential ultracentrifugation and quantified by CD63 ELISA (see 
Chapter 2 Experimental Methods), The remaining supernatant after exosome 
extraction, exosome-free conditioned medium (EF-CM), was collected and utilized 
as a control. GSC-derived and MSC-derived exosomes were then added to single-
cell suspensions of four GSC lines (Table 2) in 96-well plates at a dose of 4.0 x 102 
exosomes/µL at time zero, and at 1 week and 2 week time points. GSCs were also 
treated with NSC medium and GA-MSC-derived EF-CM. After 3 weeks of culture, 
quantification of GSC neurospheres was performed. Neurosphere formation of 
GSCs treated with GA-MSC-derived exosomes was compared to that of untreated 
GSC controls. All experiments were performed in quadruplicate and statistical 
analysis was performed utilizing the paired student’s t-test. 
Effects of GA-MSC-Derived Exosomes on GSC Tumorigenicity 
In order to isolate MSC-derived exosomes, GA-MSC 262 and GA-MSC 20 
were expanded to 5.0 x 107 cells in MSC growth medium. GA-MSCs were 
subsequently washed and incubated for 48 hours in serum-free NSC medium. 
Likewise, to isolate GSC-derived self-exosomes, GSC 262 and GSC 20 (matching 
pairs) were expanded to 1.0 x 107 cells in NSC growth medium. Both MSC-derived 
and GSC-derived exosomes were then isolated from the conditioned mediums by 
differential ultracentrifugation and quantified by CD63 ELISA (see Chapter 2 
Experimental Methods), The remaining supernatant after exosome extraction, 
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exosome-free conditioned medium (EF-CM), was collected and utilized as a control. 
Additionally, GSC 262 and GSC 20 were expanded to 3.0 x 107 cells in preparation 
for pre-treatment and implantation. GSC-derived and GA-MSC-derived exosomes 
were then added to GSC cultures at a dose of 1.0 x 109 exosomes/mL. GSCs were 
also pre-treated with NSC medium and GA-MSC-derived EF-CM. After 96 hours of 
pre-treatment, excess exosomes were eliminated by PBS wash, and GSC 
neurospheres were dissociated. GSCs were then injected into the right frontal lobe 
of nude mice (n=15/group, 5.0 x 105 cells/mouse), utilizing a cranial bolt-guided, 
stereotactic system. A cohort of mice (n=9) were followed until moribund and then 
sacrificed. Another cohort of mice (n=6) were sacrificed at 20 and 40 days post 
implantation. After sacrifice, mouse brains were removed, embedded in paraffin, and 
sectioned tumors. Tumor volumes and survival results of the GSCs treated with GA-
MSC-derived exosomes were compared to untreated GSC controls. Tumor volumes 
were calculated by adding multiple cross-sectional areas through the tumors after 
H&E staining of histologic sections. Statistical analysis was performed utilizing the 
paired student’s t-test for tumor volume analysis, and log-rank (Mantel-Cox) test for 
survival analysis. 
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3.2 Results 
GSCs Internalize GA-MSC-derived exosomes 
To confirm the localization of MSC-derived exosomes to the cytoplasm of 
GSCs, we labeled exosomes using a CD63-green fluorescent fusion protein. The 
robustness of the CD63 marker in GA-MSC-derived exosomes allowed the use of 
this CD63-GFP fusion protein for tracking. Additionally, I exploited the optical 
sectioning capabilities of fluorescent confocal microscopy for tracking of GA-MSC-
derived exosomes, instead of fluorescent light microscopy. In these experiments, 
CD63-GFP expressing GA-MSCs were cultured, and GFP labeled exosomes were 
isolated and co-cultured with GSCs (see experimental methods). After 4 hours of co-
culturing, fluorescent confocal microscopy revealed the presence of GFP-labeled 
GA-MSC-derived exosomes exclusively in the cytoplasm of GSCs, and not in the 
nucleus (Figure 27). Furthermore, GFP-labeled exosomes appeared to be grouped 
together within the cytoplasm of GSCs. Taken together, these results indicate that 
GA-MSC-derived exosomes can be internalized by GSCs. 
GA-MSC-Derived Exosomes Increase GSC Proliferation 
To determine the growth effects of MSC-derived exosomes on GSCs, I 
conducted in vitro co-culture experiments in which I assayed GSC proliferation after 
exposure to GA-MSC-derived exosomes. Specifically, GSCs and MSC were 
cultured, and exosomes isolated and co-cultured with GSCs (see experimental 
methods). Proliferation assays demonstrate that GA-MSC-derived exosomes 
significantly increased (p < 0.01, paired student’s t-test) the proliferation of GSCs in 
a dose dependent manner (Figure 28). Importantly, the exosome-mediated 
promotion of growth in GSCs was significant with the treatment of exosomes derived 
from the matching GA-MSCs isolated from the same tumor specimen. Likewise, BM-
MSC-derived exosomes also exerted growth-promoting effects on each GSC. 
However, in general the proliferation effects of the GA-MSC-derived exosomes were 
greater than that of BM-MSC-derived exosomes. As expected, and consistent with 
earlier results, treatment of GSCs with GA-MSC-derived EF-CM, also significantly  
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Figure 27. GSCs internalize fluorescently 
labeled MSC-derived exosomes. (A/B) 
Fluorescent confocal microscopy 
demonstrating the internalization of GFP-
CD63 labeled BM-MSC-derived exosomes 
by GSC 262 and GSC 20, respectively. 
Fluorescently labeled exosomes (green) are 
localized to the cytoplasm of GSCs and are 
excluded from the nucleus (DAPI stained 
blue). 
A 
B 
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Figure 28. GA-MSC-derived exosomes increase GSC proliferation. (A) Proliferation assay for GSC 
11 demonstrating a significant increase   (p < 0.01, student’s t-test) in viability with the treatment of 
GA-MSC 230-derived exosomes at two doses. As expected, treatment of GSC 11 with GA-MSC 230-
derived exosome-free conditioned medium significantly increases viability, while treatment with GSC 
11-derived self-exosomes does not have a significant effect. (B) Proliferation assay for GSC 11 
demonstrating dose dependent significant increases (p < 0.01, student’s t-test) in viability with 
treatment of exosomes derived from BM-MSC and three GA-MSC lines. 
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Figure 28. GA-MSC-derived exosomes increase GSC proliferation. (C) Proliferation assay for GSC 
7-2 demonstrating a significant increase (p < 0.01, student’s t-test) in viability with the treatment of GA-
MSC 247-derived exosomes at two doses. As expected, treatment of GSC 7-2 with GA-MSC 247-
derived exosome-free conditioned medium significantly increases viability, while treatment with GSC 7-
2-derived self-exosomes does not have a significant effect. (D) Proliferation assay for GSC 7-2 
demonstrating dose dependent significant increases (p < 0.01, student’s t-test) in viability with 
treatment of exosomes derived from BM-MSC and three GA-MSC lines. 
* p < 0.05 
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Figure 28. GA-MSC-derived exosomes increase GSC proliferation. (E) Proliferation assay for GSC 
262 demonstrating a significant increase (p < 0.01, student’s t-test) in viability with the treatment of GA-
MSC 262-derived exosomes at two doses. As expected, treatment of GSC 262 with GA-MSC 262-
derived exosome-free conditioned medium significantly increases viability, while treatment with GSC 
262-derived self-exosomes does not have a significant effect. (F) Proliferation assay for GSC 262 
demonstrating dose dependent significant increases (p < 0.01, student’s t-test) in viability with 
treatment of exosomes derived from BM-MSC and three GA-MSC lines. 
* p < 0.05 
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Figure 28. GA-MSC-derived exosomes increase GSC proliferation. (G) Proliferation assay for 
GSC 20 demonstrating a significant increase  (p < 0.01, student’s t-test) in viability with the treatment 
of GA-MSC 20-derived exosomes at two doses. As expected, treatment of GSC 20 with GA-MSC 20-
derived exosome-free conditioned medium significantly increases viability, while treatment with GSC 
20-derived self-exosomes does not have a significant effect. (H) Proliferation assay for GSC 20 
demonstrating dose dependent significant increases (p < 0.01, student’s t-test) in viability with 
treatment of exosomes derived from BM-MSC and three GA-MSC lines. 
* p < 0.05 
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increased GSC proliferation compared with untreated controls (p < 0.01, paired 
student’s t-test). In contrast, treatment of GSCs with GSC-derived self-exosomes, 
did not have a significant effect on GSC proliferation (p > 0.05, paired student’s t-
test). This finding confirms previous reports that exosomes are recycled and do not 
exert any known autocrine effects on the cell from which they are derived, as GSC-
derived self-exosomes had no effect on GSCs.190 These results indicate that 
exosome-mediated growth effects are dependent on the cell-of-origin, and that BM-
MSC-derived and GA-MSC-derived exosomes increase the proliferation of GSCs.  
GA-MSC-Derived Exosomes Increase GSC Clonogenicity 
I then evaluated the effects of MSC-derived exosomes on the ability of GSCs 
to self-replicate, by conducting in vitro co-culture experiments in which I assayed 
GSC clonogenicity after exposure to GA-MSC-derived exosomes. Specifically, 
GSCs and MSC were cultured, and exosomes isolated and co-cultured with GSCs 
(see experimental methods). Clonogenicity assays demonstrate that GA-MSC-
derived exosomes significantly increased GSC neurosphere formation and thus 
clonogenicity (p < 0.05, paired student’s t-test) (Figure 29). Importantly, the 
exosome-mediated promotion of self-renewal in GSCs was significant with the 
treatment of exosomes derived from the matching GA-MSCs isolated from the same 
tumor specimen Likewise, BM-MSC-derived exosomes also increased GSC 
clongenicity. As expected, treatment of GSCs with GA-MSC-derived EF-CM also 
increased GSC clonogenicity (p < 0.05, paired student’s t-test). In contrast, and in 
agreement with the proliferation results, treatment of GSCs with GSC-derived self-
exosomes did not have a significant effect on GSC clonogenicity (p > 0.05, paired 
student’s t-test). These results indicate that BM-MSC-derived and GA-MSC-derived 
exosomes enhance the clonogenicity of GSCs. 
GA-MSC-Derived Exosomes Enhance GSC Tumorigenicity 
I next sought to determine whether the in vitro results also occurred in vivo. 
To assess the effects of GA-MSC-derived exosomes on GSCs in vivo, I utilized GSC 
xenografts in nude mice. Specifically, GSCs and MSC were cultured, and exosomes  
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Figure 29 GA-MSC-derived exosomes increase GSC clonogenicity. (A) Clonogenic assay for GSC 
11 demonstrating a significant increase    (p < 0.01, student’s t-test) in self-renewal with the treatment of 
GA-MSC 230-derived exosomes. As expected, treatment of GSC 11 with GA-MSC 230-derived 
exosome-free conditioned medium significantly increases self-renewal, while treatment with GSC 11-
derived self-exosomes does not have a significant effect. (B) Clonogenic assay for GSC 11 
demonstrating significant increases (p < 0.01, student’s t-test) in self-renewal with treatment of 
exosomes derived from BM-MSC and three GA-MSC lines. 
* p < 0.05 
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Figure 29 GA-MSC-derived exosomes increase GSC clonogenicity. (C) Clonogenic assay for GSC 
7-2 demonstrating a significant increase   (p < 0.01, student’s t-test) in self-renewal with the treatment of 
GA-MSC 247-derived exosomes. As expected, treatment of GSC 7-2 with GA-MSC 247-derived 
exosome-free conditioned medium significantly increases self-renewal, while treatment with GSC 7-2-
derived self-exosomes does not have a significant effect. (D) Clonogenic assay for GSC 7-2 
demonstrating significant increases (p < 0.01, student’s t-test) in self-renewal with treatment of 
exosomes derived from BM-MSC and three GA-MSC lines. 
* p < 0.05 
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Figure 29 GA-MSC-derived exosomes increase GSC clonogenicity. (E) Clonogenic assay for GSC 
262 demonstrating a significant increase  (p < 0.01, student’s t-test) in self-renewal with the treatment 
of GA-MSC 262-derived exosomes. As expected, treatment of GSC 262 with GA-MSC 262-derived 
exosome-free conditioned medium significantly increases self-renewal, while treatment with GSC 262-
derived self-exosomes does not have a significant effect. (F) Clonogenic assay for GSC 262 
demonstrating significant increases (p < 0.01, student’s t-test) in self-renewal with treatment of 
exosomes derived from BM-MSC and three GA-MSC lines. 
* p < 0.05 
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Figure 29 GA-MSC-derived exosomes increase GSC clonogenicity. (G) Clonogenic assay for GSC 
20 demonstrating a significant increase (p < 0.01, student’s t-test) in self-renewal with the treatment of 
GA-MSC 20-derived exosomes. As expected, treatment of GSC 20 with GA-MSC 20-derived 
exosome-free conditioned medium significantly increases self-renewal, while treatment with GSC 20-
derived self-exosomes does not have a significant effect. (H) Clonogenic assay for GSC 20 
demonstrating significant increases (p < 0.01, student’s t-test) in self-renewal with treatment of 
exosomes derived from BM-MSC and three GA-MSC lines. 
* p < 0.05 
95 
 
isolated and co-cultured with GSCs (see experimental methods). In vivo experiments 
demonstrated that pre-treatment of GSC 262 with GA-MSC 262-derived exosomes 
significantly decreased median survival from 56 to 45 days (p < 0.05, log-rank test) 
(Figure30). Furthermore, pre-treatment of GSC 20 with GA-MSC 20-derived 
exosomes significantly decreased median survival from 49 to 37 days (p < 0.05, log-
rank test) (Figure 30). Additionally, in agreement with in vitro results, pre-treatment 
of GSC xenografts with GA-MSC-derived EF-CM also significantly decreased 
median survival (p < 0.05, log-rank test), while pre-treatment of GSCs with GSC-
derived self-exosomes did not have a significant effect on median survival (p > 0.05, 
log-rank test). 
Histologic analysis of brain specimens from mice implanted with GSC 262 
pre-treated with GA-MSC 262-derived exosomes, demonstrated a significant 
increase in tumor volume when compared to untreated GSC controls at 40 days 
post-implantation, and not at 20 days post-implantation (p < 0.01, paired student’s t-
test) (Figure 31 and Figure 32). Similarly, histologic analysis of brain specimens 
from mice implanted with GSC 20 pre-treated with GA-MSC 20-derived exosomes, 
demonstrated a significant increase in tumor volume when compared to untreated 
GSC controls at both 20 and 40 days post-implantation (p < 0.01, paired student’s t-
test) (Figure 31 and Figure 32). As expected, pre-treatment of GSCs with GA-MSC-
derived EF-CM also significantly increased tumor volume at 20 and 40 days post-
implantation (p < 0.05, paired student’s t-test). In contrast, and in agreement with in 
vitro results, treatment of GSCs with GSC-derived self-exosomes did not have a 
significant effect on tumor volume at 20 and 40 days post-implantation (p > 0.05, 
paired student’s t-test). These histologic results corroborate with survival data and 
findings from in vitro experiments. Together, these results indicate that GA-MSC-
derived exosomes significantly increase the tumorigenicity of GSCs. 
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Figure 30. GA-MSC-derived exosomes decrease median 
survival. (A) Survival curve for mice with GSC 262 xenogafts, 
demonstrating a significant decrease (p < 0.05, log-rank test) in 
median survival from 56 to 45 days with pre-treatment of GA-
MSC 262-derived exosomes. (B) Survival curve for mice with 
GSC 20 xenogafts, demonstrating a significant decrease (p < 
0.05, log-rank test) in median survival from 49 to 37 days with 
pre-treatment of GA-MSC 20-derived exosomes. 
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Figure 31. GA-MSC-derived exosomes increase tumor burden (20 days).      
(A/B) H&E staining and tumor volumes for GSC 262 xenografts 20 days post-
implantation, demonstrating no significant difference in tumor burden between the 
untreated GSC 262 control group, and GSC 262 treated with GA-MSC 262-derived 
self exosomes. 
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Figure 31. GA-MSC-derived exosomes increase tumor burden (20 days). 
(C/D) H&E staining and tumor volumes for GSC 20 xenografts 20 days post-
implantation, demonstrating no significant difference in tumor burden between the 
untreated GSC 20 control group, and GSC 20 treated with GA-MSC 20-derived 
self exosomes. 
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Figure 32. GA-MSC-derived exosomes increase tumor burden (40 days). 
(E/F) H&E staining and tumor volumes for GSC 262 xenografts 40 days post-
implantation, demonstrating a significant difference in tumor burden between the 
untreated GSC 262 control group, and GSC 262 treated with GA-MSC 262-
derived self exosomes. 
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Figure 32. GA-MSC-derived exosomes increase tumor burden (40 days). 
(GH) H&E staining and tumor volumes for GSC 262 xenografts 20 days post-
implantation, demonstrating no significant difference in tumor burden between the 
untreated GSC 20 control group, and GSC 20 treated with GA-MSC 20-derived 
self exosomes. 
GSC 20 
Untreated 
Control 
GSC 20 
+ Self-
Exosomes 
GSC 20  
+ GA-MSC 
CM 
GSC 20 
+ GA-MSC 
Exosomes 
  Animal #1                 Animal #2                  Animal #3 
* p < 0.05 
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3.3 Discussion 
 In this chapter I show for the first time that GA-MSC-derived exosomes are 
taken up by GSCs, and that these exosomes increase proliferation and clonogenicity 
of GSCs in vitro, as well as increase tumorigenicity of GSCs in vivo.  
 Paracrine communication between cells of the tumor stromal cells and tumor 
propagating cells is well described, and recent studies have implicated exosomes as 
part of this system.190-191 The majority of the literature focuses on the uptake and 
utilization of cancer stem cell-derived exosomes by the surrounding stromal cells of 
the microenvironment, although evidence supporting the internalization and usage of 
stromal-derived exosomes by cancer stem cells is mounting.77-78,125-126 For example, 
Ekstrom, et al., showed that monocyte-derived exosomes, labeled with the 
fluorescent membrane dye PKH67, were taken up by MSCs into their cytoplasm, 
while Bijnsdorp, et al., revealed that prostate epithelial cells endocytosed PKH67-
labeled colorectal cancer-derived exosomes.192-193 More related to my research in 
gliomas, Skog, et al., demonstrated that GBM-derived PKH67-labeled exosomes, 
were internalized by brain microvascular endothelial cells.80 These studies support 
the findings that fluorescent labeled exosomes can be visualized either attached to 
the membrane of within the cytoplasm of recipient cells. However, the tendency of 
this fluorescent dye, as with other lipophilic dyes, to leak out of the membrane and 
into surrounding cells suggests that they are not ideal for the labeling of exosomes. 
 To overcome the inadequacy of fluorescently labeling exosomes with the 
PKH67 membrane dye, other approaches were investigated. Evidence of a more 
reliable method for fluorescently labeling exosomes was first published by Wei, et 
al., who showed that lung cancer cell-derived exosomes could be labeled with a 
CD63-GFP fusion protein.194 This method was then utilized by Suetsugu, et al., who 
demonstrated that CD63-labeled exosomes from breast cancer cells were taken up 
by normal lung tissue cells.195 These two articles support the findings that GA-MSC-
derived exosomes can be more precisely labeled with the CD63-GFP fusion protein, 
and that GA-MSC-derived exosomes can be more clearly tracked intracellularly in 
recipient GSCs to demonstrate internalization.  
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 Although there are multiple studies exploring the intercellular communication 
between stromal cells and CSCs, few studies have investigated the role of stromal 
cell-derived exosomes in interactions with CSCs. Previous studies have indicated 
that stromal cell-derived exosomes can enhance the growth of CSCs in other cancer 
types, thereby supporting the results of my study. For example, Luga, et al., found 
that exosomes from breast cancer associated fibroblasts (CAFs) enhance the 
growth and metastasis of breast cancer cells via activation of the Wnt signaling 
pathway.125 Similarly, Zhu, et al., showed that BM-MSC-derived exosomes 
increased the tumorigenicity of gastric carcinoma and colon cancer cells via the 
ERK1/2 signaling pathway.155 Similarly, Roccaro, et al., reported that BM-MSC 
derived exosomes from patients with multiple myeloma, enhanced progression of 
multiple myeloma tumors via delivery of oncogenic proteins that affected cell 
adhesion and migration.154 Consistent with these reports, I show that BM-MSC-
derived exosomes promote the growth of CSCs in gliomas. My findings expand on 
the results of these studies by also showing that exosomes derived from a bona fide 
cell in the tumor microenvironment, GA-MSCs, also increase the growth of CSCs in 
gliomas. Furthermore, I also demonstrated that MSC-derived exosomes also 
increase the clonogenicity of CSCs in glioma, which was not investigated in these 
studies. Interestingly, GA-MSC-derived exosomes appeared to have more potent 
effects on GSC growth than BM-MSC-derived exosomes, suggesting that residence 
within the glioma niche enhances the growth promoting ability of MSCs. Therefore, 
to my knowledge, this is the first study to examine specifically the function of tumor-
derived MSCs on CSC growth and self-renewal.  
 Interestingly, Roccaro, et al., also found that BM-MSC-derived exosomes 
from normal subjects without multiple myeloma, had an inhibiting effect on CSCs.154 
My experimental results did not indicate a tumor-inhibiting function of BM-MSC-
derived exosomes, as described by Roccaro and colleagues.154 Instead, BM-MSC-
derived exosomes from normal subjects caused similar growth-promoting effects in 
GSCs as GA-MSC-derived exosomes. Nevertheless, these results define a glioma-
promoting role of GA-MSC-derived exosomes and are supported by the literature. 
Furthermore, since we previously described the glioma-promoting properties of GA-
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MSCs co-cultured with GSCs, it was not surprising that the exosomes released by 
GA-MSCs were also tumor-promoting in nature, and not tumor-inhibiting.97 It is 
unclear why the experimental results of Roccaro, et al, differ from my investigation, 
however it is reasonable to consider that the role of BM-MSCs in multiple myeloma, 
a tumor of the bone, may be different from their role in other cancers. 
 To my knowledge, there are no studies describing a tumor-inhibiting role of 
stroma-derived exosomes. Instead, researchers are utilizing the robust functionality 
of the stroma-derived exosome system as a vector to deliver anti-tumor therapies.74, 
196 The reasoning behind this therapeutic approach, is that the tumor-promoting 
properties of modified stroma-derived exosomes are masked or overcome by the 
anti-tumor properties imparted by the therapeutic molecules. In any case, the 
enhancement of tumors by stroma-derived exosomes is being evaluated 
mechanistically in a variety of cancer types. Thus, these findings necessitate future 
investigation into the mechanism responsible for the glioma-promoting effects of GA-
MSC-derived exosomes. 
 One of the weaknesses of this study was not conducting a time course 
experiment involving the tracking of fluorescently labeled GA-MSC-derived 
exosomes. This would have allowed the visualization of the exosome internalization 
process by GSCs, thus providing better insight and understanding of this intercellular 
communication pathway. Another weakness was not performing a limiting dilution for 
the study of clonogenicity in vivo. This experiment would involve implanting fewer 
and fewer GSCs pre-treated with GA-MSC-derived exosomes, in order to determine 
the least amount of cells that can form a tumor. Results from this experimental 
method would yield in vivo proof of clonogenic enhancement in GSCs, whereas 
tumor burden yields in vivo proof of only proliferative enhancement. Nevertheless, I 
did study, and show increases in, GSC growth and tumorigenicity in vivo. 
 Conversely, one of the strengths of this study was the use of matched pairs of 
GSCs and GA-MSCs that were isolated from the same patient tumor specimen. To 
my knowledge the use of such pairs in glioma studies is unique and has never been 
incorporated in research studies. This novel approach ensures that I investigated the 
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communication between cells actually present in the tumor niche, rather than 
utilizing commercially available BM-MSCs or the U87 glioblastoma cell line. 
However, I did utilize BM-MSCs in order to demonstrate the tumor-promoting 
function of MSC-derived exosomes in general. Another strength was the use of 
GSCs treated with GA-MSC-derived exosome-free conditioned medium as a positive 
control in demonstrating increases in GSC growth and self-renewal. Normal GA-
MSC-derived conditioned medium contains a low concentration of exosomes, and 
therefore should not be used as a control. Furthermore, I utilized GSCs treated with 
GSC-derived self-exosomes as a negative control to demonstrate that the tumor-
promoting properties are not universal to all exosomes, but are specific to the cell of 
origin. The last strength of this study was pre-treating GSCs with GA-MSCs in 
culture before in vivo implantation. Since I was investigating the exosomal 
communication between GA-MSCs and GSCs, this pre-treatment protocol ensured 
that GA-MSC-derived exosomes only interacted with GSCs. Conversely, co-injection 
of GSC and GA-MSC-derived exosomes would allow for exosomes to interact with 
other cells in the tumor niche.  
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3.4 Conclusions 
 The results of this investigation demonstrate for the first time that GA-MSC-
derived exosomes can be tracked utilizing both fluorescent membranes dye and 
GFP-CD63 fusion protein. Furthermore, GSCs can internalize and organize GA-
MSC-derived exosomes intracellularly. Most importantly I demonstrate that GA-
MSC-derived exosomes significantly increase the proliferation of GSCs in vitro in a 
dose dependent manner. Additionally, GA-MSC-derived exosomes can also 
increase neurosphere formation, and thus clonogenicity, of GSCs in vitro. Moreover, 
GA-MSC-derived exosomes significantly increase the tumorigenicity of GSCs in 
vivo, thereby increasing tumor burden and decreasing median survival. These 
results prove that GA-MSC-derived exosomes alter the biology of GSCs. 
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MicroRNA in GA-MSC-Derived Exosomes Promote Glioma Growth 
 
Evidence that GA-MSCs promote the growth of gliomas via exosomal miRNA 
requires identification of oncogenic miRNAs in GA-MSC-derived exosomes and 
demonstration that the miRNAs are functional in GSCs. To my knowledge such an 
analysis has never been conducted in gliomas. By investigating the role of exosomal 
miRNAs in the evolution of glioma, I hope to define a new intratumoral paracrine 
communication system. Therefore, I hypothesized that miRNA delivered via GA-
MSC-derived exosomes increase the tumorigenicity of GSCs. To test this 
hypothesis, I first identified a specific group of miRNAs which were both highly 
expressed and highly enriched in GA-MSC-derived exosomes. I then compared 
expression levels for predicted gene targets of this group of exosomal miRNAs in 
untreated GSCs with those in GSCs after treatment with GA-MSC-derived 
exosomes. These results established a functional connection between miRNAs in 
GA-MSC-derived exosomes and recipient GSCs. I then showed that the growth and 
self-renewal of GSCs are increased by over-expression of these exosomal miRNAs 
in GSCs in vitro. These findings established that GA-MSCs alter the proliferation and 
clonogenicity of GSCs by secreting exosomes carrying specific miRNA. In the future, 
I aim to demonstrate that miRNA in GA-MSC-derived exosomes increase the 
tumorigenicity of GSCs in vivo. 
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4.1 Experimental Methods 
Identification of Key MicroRNAs in GA-MSC-Derived Exosomes 
 In order to identify miRNAs that were not only highly expressed in MSC-
derived exosomes (Table 5), but also highly enriched, I utilized the miRNA profiles 
obtained from earlier experiments (see Chapter 2 Experimental Methods). Out of the 
2,019 miRNA analyzed, I identified a sub-population of miRNA that had significantly 
different average levels of expression between the MSC-derived exosomes and the 
parental cell (p < 0.05, paired student’s t-test). This sub-population was termed 
enriched in MSC-derived exosomes. The change in expression for each enriched 
miRNA was then calculated by taking the difference in average expression levels 
between the MSC-derived exosome and the parental cell. MicroRNA that had 
expression changes greater than 2 standard deviations from the mean (top 2.5%) 
were termed highly enriched miRNA.  
 In order to identify miRNA in the enriched subpopulation that were also the 
most highly expressed in MSC-derived exosomes, an expression-to-enrichment ratio 
(E:R ratio) was calculated, by multiplying the change in expression between the 
exosome and the parental cell, by the ratio of expression levels between the 
exosome and the parental cell. 
E:R ratio = (Exosome – Cell) x (Exosome / Cell) 
 The E:R ratio yielded two groups of miRNAs at the extremes of the 
distribution. One group of miRNA was both highly expressed and highly enriched in 
MSC-derived exosomes when compared to the MSC parental cell. Another group of 
miRNA was both highly expressed and highly enriched in parental MSCs, and thus 
had low expression and was depleted from MSC-derived exosomes. 
Identification of Nucleotide Motifs in Exosome Enriched and Depleted MicroRNA 
 In order to determine if specific nucleotide motifs in miRNA correlate with 
preferential packaging into exosomes, pre-miRNA (stem-loop) and mature miRNA 
sequences were obtained from the miRBase database for the highly enriched and 
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highly expressed miRNA in MSC-derived exosomes.197 Pre-miRNA and mature-
miRNA sequences were initially analyzed for their degree of guanine-cytosine to 
uracil-adenine (G-C:U-A) ratio. Additionally, pre-miRNA and mature-miRNA 
sequences were evaluated to identify specific sub-sequences that were common 
among the highly expressed and highly enriched miRNA groups. Statistical analysis 
was performed utilizing the paired student’s t-test.  
Gene Expression Profiling of GSCs Treated with GA-MSC-Derived Exosomes 
 In order to isolate MSC-derived exosomes, GA-MSC 262 and GA-MSC 20 
were expanded to 5.0 x 106 cells in MSC growth medium. GA-MSCs were 
subsequently washed and incubated for 48 hours in serum-free NSC medium. GA-
MSC-derived exosomes were then isolated from the conditioned mediums by 
differential ultracentrifugation and quantified by CD63 ELISA (see Chapter 2 
Experimental Methods). GA-MSC-derived exosomes were then added to GSC 
cultures (1.0 x 109 exosomes/mL). GSCs were also treated with NSC medium as a 
control. After 48 hours of treatment, excess exosomes were removed by PBS wash, 
and total RNA was isolated from both groups of GSCs (see Chapter 2 Experimental 
Methods). Total RNA from both groups of GSCs was then analyzed for gene 
expression profiling utilizing Illumina next-generation sequencing technology, 
through LC Sciences. Gene expression profiles from untreated GSCs and GSCs 
after treatment with GA-MSC-derived exosomes were statistically compared by 
paired student’s t-test. 
Gene Target Analysis of Exosome Enriched and Depleted MicroRNA 
 I identified predicted gene targets for the 8 highly enriched and highly 
expressed miRNA in MSC-derived exosomes, utilizing the miRTarget 2.0 database 
(> 80 target score).198 I then assessed the expression level of the predicted gene 
targets for the 8 highly expressed and highly enriched miRNA in GSCs after 
treatment with GA-MSC-derived exosomes, by querying the relative gene 
expression profile. Specifically, the level of expression for a given miRNA gene 
target in untreated GSCs controls was compared to that of GSCs treated with GA-
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MSC-derived exosomes. This analysis yielded an average fold change for each 
predicted gene target of the 8 highly expressed and highly enriched miRNA. By the 
same method, I also performed analysis for the predicted gene targets of the 8 
miRNA that are depleted from GA-MSC-derived exosomes. The average fold 
change among the predicted gene targets for highly enriched and highly expressed 
miRNA in GA-MSC-derived exosomes, was then compared to that of the depleted 
miRNA by performing un-paired student’s t-test. 
Over-Expression of MicroRNAs in GSCs 
 To test the effects of highly expressed and highly enriched exosomal miRNA 
on GSCs, each miRNA was over-expressed in GSCs by lentiviral (LV) transduction. 
Initially, plasmids of LV-GFP-miRNA constructs for each specific miRNA, as well as 
LV-GFP-miRNA-scramble construct (control), were isolated from expanded bacterial 
stocks (Qiagen) using a plasmid maxi kit (Qiagen). Lentiviral vectors were generated 
by transfecting human embryonic kidney 293FT (HEK-293FT) cells with individual 
miRNA plasmids, along with a viral packaging plasmid and a viral envelope plasmid. 
Resulting lentiviral (LV) vectors were isolated by ultracentrifugation of conditioned 
medium from HEK-293 cells. Viral titers were then calculated by inoculation of HEK-
293 cells with limiting dilutions of complete LV-GFP-miRNA viral vectors, and 
assessing for GFP expression. Each LV-GFP-miRNA viral vector was then 
transduced in GSC 262 and GSC 20 (1.0 x 10 6 cells) at a multiplicity of infection 
(MOI) of 3, and cultured under puromycin selection (1nM) for 72 hours. Integration of 
the GFP-miRNA construct was assessed by fluorescent light microscopy. RNA was 
then isolated from each of the GFP-miRNA transduced cell lines (see Chapter 2 
Experimental Methods) for verification of miRNA over-expression by qRT-PCR. 
Additionally, RNA was also isolated from GSCs treated with NSC medium, as well 
as from GSCs treated with GA-MSC-derived exosomes for a period of 48 hours. The 
level of miRNA expression determined by qRT-PCR for the GFP-miRNA expressing 
GSCs was then compared to that of untreated GSC controls and GSCs after 
treatment with GA-MSC-derived exosomes. Statistical analysis was performed 
utilizing paired student’s t-test.     
111 
 
Functional Verification of Over-Expressed miRNA in GSCs 
 GSCs stably expressing the GFP-miR construct were expanded to 106 cells, 
and protein isolated by the addition of cell lysis buffer (see Chapter 2 Experimental 
Methods). Additionally, GSCs were expanded to 1.0 x 106 cells and treated with NSC 
medium, GA-MSC-derived exosomes (1.0 x 109 exosomes/mL), and GA-MSC-
derived exosomes plus anti-miRNA (Qiagen) at 1nM. After 48 hours of culture, 
excess exosomes were removed by PBS wash, and protein was isolated by the 
addition of cell lysis buffer (see Chapter 2 Experimental Methods). Specific predicted 
gene targets for each over-expressed miRNA were then assessed for degree of 
down-regulation by western blot analysis. Results were compared with the degree of 
miRNA gene target expression in GSCs after treatment with NSC medium, after 
treatment with GA-MSC-derived exosomes, and after treatment with GA-MSC-
derived exosomes plus anti-miR inhibitors (Qiagen) at 1nM.  
Effects of Exosomal MicroRNAs on GSC Proliferation 
In order to isolate MSC-derived exosomes, GA-MSC 262 and GA-MSC 20 
were expanded to 5.0 x 106 cells in MSC growth medium. GA-MSCs were 
subsequently washed and incubated for 48 hours in serum-free NSC medium. MSC-
derived and GSC-derived exosomes were then isolated from the conditioned 
mediums by differential ultracentrifugation and quantified by CD63 ELISA (see 
Chapter 2 Experimental Methods). GSC 262 and GSC 20 were then placed in 16 
wells of a 96-well plate (2.5 x 103 cells/well). Four the wells were treated with NSC 
medium. Another four wells were treated with GA-MSC-derived exosomes (1.0 x 104 
exosomes/µL). Another four wells were treated with GA-MSC-derived exosomes (1.0 
x 104 exosomes/µL) plus anti-miRNA (Qiagen) by lipofection at 1nM. The last four 
wells were treated with anti-miRNA (Qiagen) by lipofection at 1nM. Additionally, 
neurospheres from GSCs expressing the GFP-miRNA constructs were dissociated 
and placed into another four wells of the 96-well plate (2.5 x 103 cells/well). Finally, 
neurospheres of GSCs expressing the GFP-miRNA-scramble construct (control) 
were placed into another four wells of the 96-well plate (2.5 x 103 cells/well). After 96 
hours of incubation, GSC viability was assessed using a colorimetric assay WST-1 
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(Roche), and the absorbance measured at 450nm. The absorbance for each 
experimental treatment group of GSCs was compared to that of untreated GSC 
controls, as well as to that of GSCs expressing the GFP-miRNA-scramble construct. 
All experiments were performed in quadruplicate and statistical analysis was 
performed utilizing the paired student’s t-test. 
Effects of Exosomal MicroRNAs on GSC Clonogenicity 
 In order to isolate MSC-derived exosomes, GA-MSC 262 and GA-MSC 20 
were expanded to 5.0 x 106 cells in MSC growth medium. GA-MSCs were 
subsequently washed and incubated for 48 hours in serum-free NSC medium. MSC-
derived and GSC-derived exosomes were then isolated from the conditioned 
mediums by differential ultracentrifugation and quantified by CD63 ELISA (see 
Chapter 2 Experimental Methods). Neurospheres from GSC 262 and GSC 20 were 
then dissociated and placed into single cell suspensions in each well of four 96-well 
plates. One 96-well plate was treated with NSC medium. Another 96-well plate was 
treated with GA-MSC-derived exosomes (4.0 x 102 exosomes/µL). Another 96-well 
plate was treated with GA-MSC-derived exosomes (4.0 x 102 exosomes/µL) plus 
anti-miRNA (Qiagen) by lipofection at 1nM. The last 96-well plate was treated with 
anti-miRNA (Qiagen) by lipofection at 1nM. Additionally, neurospheres from GSCs 
expressing the GFP-miRNA constructs were dissociated and placed into single cell 
suspension in each well of another 96-well plate. Finally, neurospheres from GSCs 
expressing the GFP-miRNA-scramble construct (control) were dissociated and 
placed into single cell suspension in each well of another 96-well plate. After 3 
weeks of incubation, GSC neurospheres in all 96-well plates were quantified. 
Percentage of neurosphere formation in each GSCs experimental group was 
compared to that of untreated GSC controls, as well as to that of GSCs expressing 
the GFP-miRNA-scramble construct. All experiments were performed in 
quadruplicate and statistical analysis was performed utilizing paired student’s t-test.  
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Effects of Exosomal MicroRNAs on GSC Tumorigenicity 
GA-MSC 262 and GA-MSC 20 were expanded to 5.0 x 107 cells in MSC 
growth medium. Exosomes were isolated from conditioned medium of GA-MSC 262 
and GA-MSC 20 by differential ultracentrifugation, and quantified by CD63 ELISA. 
Subsequently, GSC 262 and GSC 20 were expanded to 3.0 x 107 cells in 
preparation for pre-treatment and implantation. GSCs were then pre-treated with 
either NSC medium, GA-MSC-derived exosomes (1.0 x 109 exosomes/mL), GA-
MSC-derived exosomes (1.0 x 109 exosomes/mL) plus anti-miR (Qiagen) by 
lipofection at 1nM, and anti-miR (Qiagen) by lipofection at 1nM. Additionally, GSCs 
expressing the GFP-miRNA construct, and GSCs expressing the GFP-miRNA-
scramble construct, we expanded to 7.5 x 106 cells each. After 96 hours of pre-
treatment, excess exosomes were eliminated by PBS wash, and GSC neurospheres 
were dissociated. GSCs were then injected into the right frontal lobe of nude mice 
(n=15/group, 5.0 x 105 cells/mouse), utilizing a cranial bolt-guided, stereotactic 
system. A cohort of mice (n=9) were followed until moribund and then sacrificed. 
Another cohort of mice (n=6) were sacrificed at 20 and 40 days post implantation. 
After sacrifice, mouse brains were removed, embedded in paraffin, and sectioned 
tumors. Tumor volumes and survival results of the GSCs treated with GA-MSC-
derived exosomes were compared to untreated GSC controls. Tumor volumes were 
calculated by adding multiple cross-sectional areas through the tumors after H&E 
staining of histologic sections. Statistical analysis was performed utilizing the paired 
student’s t-test for tumor volume analysis, and log-rank test for survival analysis. 
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4.2 Results 
Identification of Key MicroRNA in GA-MSC-Derived Exosomes 
 To identify potential miRNA in MSC-derived exosomes that could be causing 
the increase in GSC tumorigenicity, I first evaluated the miRNA profiles of exosomes 
from BM-MSCs and four GA-MSC lines (see Chapter 2 Results). I identified a sub-
population of miRNA that were highly enriched in MSC-derived exosomes when 
compared to the parental cell, with changes in expression greater than 4000 
hybridization intensity (> 2 standard deviations from the mean) (Table 6). I then 
calculated the expression-to-enrichment ratio (E:R ratio) for each miRNA, and 
graphed the distribution of the E:R ratios (Figure 33). From one extreme of this 
distribution, I identified a group of 8 miRNAs that were the most highly expressed 
and highly enriched (> 3 standard deviations from the mean) in MSC-derived 
exosomes when compared to the parental cells (Table 7). This cutoff correlated with 
average miRNA expression levels greater than 5000 hybridization intensity. 
Conversely, from the other extreme of the distribution, I identified a group of 8 
miRNA that were the most highly expressed and highly enriched (> 1 standard 
deviation from the mean) in the parental cells when compared to MSC-derived 
exosomes (Table 7). The group of miRNA that are highly expressed and highly 
enriched in the parental cells are thus relatively depleted from MSC-derived 
exosomes. This level of enrichment and depletion suggests the existence of a 
mechanism which targets miRNAs into, or out of, MSC-derived exosomes. 
 Interestingly, the nucleotide composition of both the enriched and depleted 
miRNAs in GA-MSC-derived exosomes are significantly different from each other. 
Specifically, the Glutamine-Cytosine to Adenine-Uracil ratio (G-C:A-U) for the group 
of enriched miRNAs is 2.12:1 in pre-miRNA, and 3.20:1 in mature miRNA (Table 8). 
Conversely, the G-C:U-A ratio for the group of depleted miRNAs is 0.65:1 in pre-
miRNA, and 0.72:1 in mature miRNA (Table 8). Thus, there is significantly greater 
amount of G-C nucleotides, compared to U-A nucleotides, in miRNA that are 
enriched in GA-MSC-derived exosomes (p < 0.01). Furthermore, analysis of the 
stem-loop miRNA sequences in both the enriched and depleted miRNA in GA-MSC- 
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Table 6. MSC-derived exosomes contain highly enriched 
miRNA. MSC-derived exosomes contain 24 miRNA with a 
change in expression level from the parental cell greater than 
4000 hybridization intensity (> 2.0 standard deviations from 
the mean).   
Highly Enriched   
miRNA
Expression 
Level     
Cell
Expression 
Level 
Exosome
Δ 
Expression
Standard 
Deviation
hsa-miR-3960 4,136 19,651 15516 7.710
hsa-miR-6087 2,757 15,568 12811 6.365
hsa-miR-3665 4,030 16,364 12334 6.128
hsa-miR-6089 3,903 16,163 12260 6.091
hsa-miR-1246 563 11,941 11377 5.652
hsa-miR-6090 2,398 12,200 9803 4.869
hsa-miR-4508 644 10,268 9624 4.780
hsa-miR-4497 1,994 10,837 8843 4.392
hsa-miR-574-5p 1,483 9,568 8085 4.015
hsa-miR-1234-5p 1,558 9,568 8011 3.978
hsa-miR-6125 2,153 9,926 7773 3.860
hsa-miR-4530 657 8,426 7769 3.858
hsa-miR-4505 258 7,911 7653 3.800
hsa-miR-3620-5p 268 6,373 6105 3.030
hsa-miR-3656 1,059 7,110 6050 3.003
hsa-miR-4516 2,450 8,252 5802 2.880
hsa-miR-4787-5p 1,764 7,561 5797 2.877
hsa-miR-638 1,686 7,482 5796 2.877
hsa-miR-4492 176 5,726 5550 2.755
hsa-miR-4507 185 5,398 5213 2.587
hsa-miR-574-3p 2,743 7,882 5139 2.550
hsa-miR-1587 198 5,269 5071 2.516
hsa-miR-6085 457 5,046 4589 2.276
hsa-miR-4484 868 5,069 4201 2.084
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Figure 33. GA-MSC-derived exosomes contain highly expressed 
and highly enriched miRNA. Distribution of the E:R ratio for miRNA in 
MSC-derived exosomes. Exosome-enriched miRNA were both highly 
expressed compared to exosome-depleted miRNA, which were both 
highly expressed in the parental MSC. 
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Table 7. MSC-derived exosomes contain enriched and depleted 
miRNA. (A) MSC-derived exosomes contain 8 miRNA which are the 
most highly expressed and highly enriched when compared to the 
parental cell (> 3.0 standard deviations from the mean). (B) MSC-
derived exosomes are depleted of 8 miRNA which are the most highly 
expressed and highly enriched in the parental MSC (> 1.0 standard 
deviations from the mean). 
A 
B 
Enriched miRNA
Expression 
Level    
Cell
Expression 
Level 
Exosome
Δ 
Expression
E:R ratio
Standard 
Deviation
hsa-miR-1246 563 11,941 11377 241097 8.438
hsa-miR-4505 258 7,911 7653 234683 8.212
hsa-miR-4492 176 5,726 5550 180857 6.314
hsa-miR-4508 644 10,268 9624 153480 5.349
hsa-miR-4507 185 5,398 5213 151764 5.288
hsa-miR-3620-5p 268 6,373 6105 144924 5.047
hsa-miR-1587 198 5,269 5071 134920 4.695
hsa-miR-4530 657 8,426 7769 99625 3.450
Depleted miRNA
Expression 
Level    
Cell
Expression 
Level 
Exosome
Δ 
Expression
E:R ratio
Standard 
Deviation
hsa-miR-376c-3p 2,130 149 -1981 -28384 -1.063
hsa-miR-9-3p 1,361 57 -1304 -30875 -1.150
hsa-miR-103a-3p 3,450 334 -3116 -32169 -1.196
hsa-miR-107 3,719 383 -3337 -32436 -1.205
hsa-miR-9-5p 2,994 151 -2843 -56255 -2.045
hsa-miR-4521 966 14 -952 -65330 -2.365
hsa-miR-4284 2,729 64 -2666 -114478 -4.098
hsa-miR-199a-5p 2,599 50 -2549 -132188 -4.722
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G-C % U-A% G-C % U-A%
miR-9-3p 32.91 67.09 28.57 71.43
miR-9-5p 32.91 67.09 34.78 65.22
miR-103a-3p 48.72 51.28 47.83 52.17
miR-107 46.91 53.09 50.00 50.00
miR-199a-5p 50.70 49.30 50.00 50.00
miR-376c-3p 28.79 71.21 38.10 61.90
miR-4284 32.53 67.47 30.43 69.57
miR-4521 41.67 58.33 54.55 45.45
Average 39.39 60.61 41.78 58.22
Std Dev
p-value
Mature miRNA SequenceDepleted 
miRNA
Pre-miRNA Sequence
8.87 10.00
0.005 0.027
Table 8. Exosomal miRNAs have varying nucleotide ratios. 
(A) MicroRNAs enriched in GA-MSC-derived exosomes contain 
significantly higher percentages of G-C nucleotides compared to 
U-A nucleotides. (B) MicroRNAs depleted in GA-MSC-derived 
exosomes contain significantly lower percentages of G-C 
nucleotides compared to U-A nucleotides. 
G-C % U-A% G-C % U-A%
miR-1246 43.84 56.16 42.11 57.89
miR-1587 60.38 39.62 66.67 33.33
miR-3620-5p 70.89 29.11 81.82 18.18
miR-4492 76.25 23.75 94.12 5.88
miR-4505 68.49 31.51 72.22 27.78
miR-4507 67.31 32.69 75.00 25.00
miR-4508 80.00 20.00 93.75 6.25
miR-4530 76.79 23.21 77.78 22.22
Average 67.99 32.01 75.43 24.57
Std Dev
p-value
Pre-miRNA Sequence Mature miRNA SequenceEnriched 
miRNA
16.6011.59
0.002 0.002
A 
B 
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derived exosomes, reveals three conserved 4 nucleotide-long sub-sequences that 
are specific to each group. The combination of the sub-sequences GGCU, GGAC, 
and CAGG are found in 100% of the miRNA enriched in MSC-derived exosomes, 
and not found together in any of the miRNA depleted from MSC-derived exosomes 
(Table 9). Conversely, the combination of the sub-sequences UGUU, UGUA, and 
UGUG are found in 100% of the miRNA depleted in MSC-derived exosomes, and 
are not found together in any of the miRNA enriched in MSC-derived exosomes 
(Table 9). This suggests that specific nucleotide motifs, as well as certain levels of 
G-C:U-A enrichment, may lead to particular miRNAs being preferentially packaged 
into MSC-derived exosomes.    
Verification of Exosomal MicroRNA Functionality 
 In order to determine whether the enriched miRNA in GA-MSC-derived 
exosomes are capable of affecting gene expression in GSCs, I first identified 
predicted gene targets for this group of miRNAs. Specifically, utilizing the miRTarget 
2.0 database, I identified 251 unique predicted gene targets for the 7 of the 8 highly 
expressed and highly enriched miRNA in MSC-derived exosomes (no predicted 
gene targets for miR-4508) (Table 10).198 Conversely, utilizing the miRTarget 2.0 
database, I identified 245 unique predicted gene targets for all 8 of the miRNAs that 
are depleted from MSC-derived exosomes (Table 10).198 Expression levels for the 
predicted gene targets in the two groups were then obtained from the gene 
expression profiling performed on GSC 262 and GSC 20. The expression level of 
the predicted gene targets in untreated GSCs were compared with that of GSCs 
treated with GA-MSC-derived exosomes. The fold change in expression of the 251 
predicted gene targets for the 7 enriched miRNA, was significantly more (p < 0.01) 
than the average fold change in expression of the 245 predicted gene targets for the 
8 depleted miRNA (Figure 34). These results indicate that highly expressed and 
highly enriched miRNA in GA-MSC-derived exosomes are capable of down-
regulating their predicted gene targets in GSCs. These findings also indicate that the 
predicted gene targets for depleted miRNA were not as down-regulated in GSCs 
after treatment with GA-MSC-derived exosomes, due to their low expression level.  
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Figure 34. Predicted gene targets of exosome enriched 
miRNA are down-regulated after treatment of GSCs with 
GA-MSC-derived exosomes. Change in expression level 
for predicted targets of exosome enriched miRNA, versus 
that of exosome depleted miRNA, demonstrating a 
significant difference (p < 0.001, Wilcoxon test) after 
treatment of GSCs with GA-MSC-derived exosomes for 48 
hours. The average and median fold change of predicted 
targets for exosome depleted miRNA was -0.53 and -1.84, 
respectively. The average and median fold change of 
predicted targets for exosome enriched miRNA was -3.79 
and -3.09, respectively.  
     Depleted miRNA      Enriched miRNA                            
     Predicted Targets    Predicted Targets 
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MicroRNA in GA-MSC-Derived Exosomes Increase GSC Proliferation 
 To determine the direct influence of the GA-MSC-derived exosome enriched 
miRNA on GSC proliferation, I evaluated effects on proliferation after the over-
expression of these miRNA in GSCs. Specifically, I utilized lentiviral transduction to 
over-express each of the 7 enriched exosomal miRNAs that had predicted gene 
targets in GSC 262 and GSC 20. Over-expression of miRNA was verified by qRT-
PCR analysis of RNA isolated from lentiviral transduced GSCs (Figure 35). 
Importantly, increases in expression of the 7 enriched exosomal miRNA were also 
seen in qRT-PCR analysis of GSCs after treatment with GA-MSC-derived exosomes 
(Figure 35). Of the 7 miRNAs evaluated, only the over-expression of miR-1587 and 
miR-3620-5p produced significant increases (p < 0.05) in proliferation of GSCs, 
which were similar to that of GSCs after treatment with GA-MSC-derived exosomes 
(Figure 36). GSC proliferation was also increased with the transduction of miR-
1246, however the affect was not significant (p > 0.05). Interestingly, GSC 
proliferation was also increased after the transduction of the LV-GFP-miR-scramble 
construct, however not to the degree of GSCs after treatment with GA-MSC-derived 
exosomes. These results indicate that both miR-1587 and miR-3620-5p are capable 
of increasing GSC proliferation.  
MicroRNA in GA-MSC-Derived Exosomes Increase GSC Clonogenicity 
 To determine the direct influence of the GA-MSC-derived enriched miRNA on 
GSC clonogenicity, I evaluated the effects on clonogenicity after over-expression of 
these miRNA in GSCs. Specifically, I utilized lentiviral transduction to over-express 
each of the 7 enriched exosomal miRNA that had predicted gene targets in GSC 262 
and GSC 20. Of the 7 miRNAs evaluated, only the over-expression of miR-1587 
produced a significant increase (p < 0.05) in clonogenicity of GSCs, which was 
similar to that of GSCs after treatment with GA-MSC-derived exosomes (Figure 37). 
GSC proliferation was also increased with the transduction of miR-3620-5p, however 
the affect was not significant (p > 0.05). Interestingly GSC clonogenicity was not 
affected after transduction with the LV-GFP-miR-scramble construct. These results 
indicate that only miR-1587 is capable of increasing GSC clonogenicity. 
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Figure 35. Lentiviral transduction of miRNA constructs increases 
expression in GSCs. (A) qRT-PCR data for GSC 262 demonstrating 
significant fold increases in all enriched exosomal miRNA after delivery of 
GA-MSC 262-derived exosomes. (B) qRT-PCR data for GSC 262 
demonstrating no significant increases in enriched exosomal miRNA after 
transduction with the LV-miR-scramble construct. (C) qRT-PCR data for 
GSC 262 demonstrating a significant increase in miR-1246 after 
transduction with the LV-miR-1246 construct. 
A 
* p < 0.05 
* p < 0.05 
B 
C 
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Figure 35. Lentiviral transduction of miRNA constructs increases 
expression in GSCs. (D) qRT-PCR data for GSC 262 demonstrating a 
significant increase in miR-1587 after transduction with the LV-miR-1587 
construct. (E) qRT-PCR data for GSC 262 demonstrating a significant 
increase in miR-3620-5p after transduction with the LV-miR-3620-5p 
construct. (F) qRT-PCR data for GSC 262 demonstrating a significant 
increase in miR-4492 after transduction with the LV-miR-4492 construct. 
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Figure 35. Lentiviral transduction of miRNA constructs increases 
expression in GSCs. (G) qRT-PCR data for GSC 262 demonstrating a 
significant increase in miR-4505 after transduction with the LV-miR-4505 
construct. (H) qRT-PCR data for GSC 262 demonstrating a significant 
increase in miR-4507 after transduction with the LV-miR-4507 construct.    
(I) qRT-PCR data for GSC 262 demonstrating a significant increase in miR-
4530 after transduction with the LV-miR-4530 construct. 
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Figure 35. Lentiviral transduction of miRNA constructs increases 
expression in GSCs. (A) qRT-PCR data for GSC 20 demonstrating 
significant fold increases in all enriched exosomal miRNA after delivery of 
GA-MSC 262-derived exosomes. (B) qRT-PCR data for GSC 20 
demonstrating no significant increases in enriched exosomal miRNA after 
transduction with the LV-miR-scramble construct. (C) qRT-PCR data for 
GSC 20 demonstrating a significant increase in miR-1246 after transduction 
with the LV-miR-1246 construct. 
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Figure 35. Lentiviral transduction of miRNA constructs increases 
expression in GSCs. (D) qRT-PCR data for GSC 20 demonstrating a 
significant increase in miR-1587 after transduction with the LV-miR-1587 
construct. (E) qRT-PCR data for GSC 20 demonstrating a significant 
increase in miR-3620-5p after transduction with the LV-miR-3620-5p 
construct. (F) qRT-PCR data for GSC 20 demonstrating a significant 
increase in miR-4492 after transduction with the LV-miR-4492 construct. 
130 
 
 
 
 
 
 
  
0
500
1000
miR-16 miR-1246 miR-1587 miR-3620 miR-4492 miR-4505 miR-4507 miR-4530
F
o
ld
 C
h
a
n
g
e
 O
v
e
r 
 
U
n
tr
e
a
te
d
 C
o
n
tr
o
ls
 GSC + LV-miR-4505 
0
500
1000
miR-16 miR-1246 miR-1587 miR-3620 miR-4492 miR-4505 miR-4507 miR-4530
F
o
ld
 C
h
a
n
g
e
 O
v
e
r 
 
U
n
tr
e
a
te
d
 C
o
n
tr
o
ls
 GSC + LV-miR-4507 
0
500
1000
miR-16 miR-1246 miR-1587 miR-3620 miR-4492 miR-4505 miR-4507 miR-4530
F
o
ld
 C
h
a
n
g
e
 O
v
e
r 
 
U
n
tr
e
a
te
d
 C
o
n
tr
o
ls
 GSC + LV-miR-4530 
* p < 0.05 
* p < 0.05 
P 
Q 
R 
Figure 35. Lentiviral transduction of miRNA constructs increases 
expression in GSCs. (G) qRT-PCR data for GSC 20 demonstrating a 
significant increase in miR-4505 after transduction with the LV-miR-4505 
construct. (H) qRT-PCR data for GSC 20 demonstrating a significant 
increase in miR-4507 after transduction with the LV-miR-4507 construct.    
(I) qRT-PCR data for GSC 20 demonstrating a significant increase in miR-
4530 after transduction with the LV-miR-4530 construct. 
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Figure 36. Over-expression of specific exosome enriched miRNA increases proliferation in GSCs. 
(A) Proliferation assay for GSC 262 over-expressing miRNA that are enriched in GA-MSC-derived 
exosomes, demonstrating a significant increase in GSC viability with the over-expression of miR-1587 
and miR-3620-5p. As expected, treatment of GSC 262 with GA-MSC 262 derived exosomes, also 
significantly increased viability. (B) Proliferation assay for GSC 20 over-expressing miRNA that are 
enriched in GA-MSC-derived exosomes, demonstrating a significant increase in GSC viability with the 
over-expression of miR-1587 and miR-3620-5p. As expected, treatment of GSC 20 with GA-MSC 20 
derived exosomes, also significantly increased viability. 
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B 
* p < 0.05 
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Figure 37. Over-expression of miR-1587 in GSCs increases proliferation. (A) Proliferation assay for 
GSC 262 over-expressing miR-1587, demonstrating a significant increase in GSC viability similar to that 
of treatment with GA-MSC 262-derived exosomes. This increase in GSC viability was reversible with the 
addition of a miR-1587 inhibitor. (B) Proliferation assay for GSC 20 over-expressing miR-1587, 
demonstrating a significant increase in GSC viability similar to that of treatment with GA-MSC 20-
derived exosomes. This increase in GSC viability was reversible with the addition of a miR-1587 
inhibitor. . 
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B 
* p < 0.05 
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MicroRNA-1587 in GA-MSC-Derived Exosomes Increases GSC Proliferation 
 To evaluate a causal role of miR-1587 in the proliferation effects produced by 
GA-MSC-derived exosomes on GSCs, I conducted further proliferation assays 
aimed at inhibiting miR-1587. Specifically, I treated GSCs with GA-MSC-derived 
exosomes and anti-miR-1587 by lipofection, and compared results to GSCs treated 
with GA-MSC-derived exosomes. As expected, the treatment of GSC with GA-MSC-
derived exosomes significantly increased proliferation, and was able to be partially 
reversed with the addition of anti-miRNA-1587 (Figure 38). Importantly, GSC 
proliferation was not affect by treatment with anti-miRNA alone. This indicates that 
miR-1587 contained within GA-MSC-derived exosomes has a causal role in 
increasing the proliferation of GSCs. 
MicroRNA-1587 in GA-MSC-Derived Exosomes Increases GSC Clonogenicity 
 To evaluate a causal role of miR-1587 in the self-renewal effects produced by 
GA-MSC-derived exosomes on GSCs, I conducted further clonogenicity assays 
aimed at inhibiting miR-1587. Specifically, I treated GSCs with GA-MSC-derived 
exosomes and anti-miR-1587 by lipofection, and compared results to GSCs treated 
with GA-MSC-derived exosomes. As expected, the treatment of GSC with GA-MSC-
derived exosomes significantly increased clonogenicity, and was able to be partially 
reversed with the addition of anti-miRNA-1587 (Figure 39). Importantly, GSC 
clonogenicity was not affect by treatment with anti-miRNA alone. This indicates that 
miR-1587 contained within GA-MSC-derived exosomes has a causal role in 
increasing the clonogenicity of GSCs. 
Verification of miR-1587 Functionality in GSCs 
 Given that miR-1587 most significantly increased proliferation and 
clonogenicity in GSCs when compared to the other six highly expressed and highly 
enriched exosomal miRNAs, I assessed its functionality by directly analyzing one of 
its gene targets. Specifically, I focused on a major predicted target of miR-1587, the 
nuclear hormone receptor co-repressor-1 (NCOR1), which had a predicted targeting 
score of 90 (miRTarget 2.0 database).198 I evaluated the expression of NCOR1 in  
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Figure 38. Over-expression of specific exosome enriched miRNA in GSCs increases 
clonogenicity. (A) Clonogenic assay for GSC 262 over-expressing miRNA that are enriched in GA-
MSC-derived exosomes, demonstrating a significant increase in GSC clonogenicity with the over-
expression of miR-1587. As expected, treatment of GSC 262 with GA-MSC 262 derived exosomes, 
also significantly increased clonogenicity. (B) Clonogenic assay for GSC 20 over-expressing miRNA 
that are enriched in GA-MSC-derived exosomes, demonstrating a significant increase in GSC 
clonogenicity with the over-expression of miR-1587. As expected, treatment of GSC 20 with GA-MSC 
20 derived exosomes, also significantly increased clonogenicity. 
GSC 262 
GSC 20 
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Figure 39. Over-expression of miR-1587 in GSCs increases clonogenicity. (A) Clonogenic assay for 
GSC 262 over-expressing miR-1587, demonstrating a significant increase in GSC clonogenicity similar 
to that of treatment with GA-MSC 262-derived exosomes. This increase in GSC clonogenicity was 
reversible with the addition of a miR-1587 inhibitor. (B) Clonogenic assay for GSC 20 over-expressing 
miR-1587, demonstrating a significant increase in GSC clonogenicity similar to that of treatment with 
GA-MSC 20-derived exosomes. This increase in GSC clonogenicity was reversible with the addition of a 
miR-1587 inhibitor. . 
A 
B 
* p < 0.05 
GSC 262 
GSC 20 
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untreated GSC controls, GSCs over-expressing GFP-miR-1587, GSCs treated with 
GA-MSC-derived exosomes, and GSCs treated with GA-MSC-derived exosomes 
plus anti-miR-1587. As expected, over-expression of miR-1587 in GSCs, and 
treatment of GSCs with GA-MSC-derived exosomes, decreased the expression of 
NCOR1, when compared to untreated GSC controls (Figure 40). Most importantly, 
treatment of GSCs with GA-MSC-derived exosomes plus anti-mir-1587 inhibitor 
partially reversed the negative regulation of NCOR1. These results indicate that 
regulation of NCOR1 in GSCs by miR-1587 in GA-MSC-derived exosomes, plays a 
crucial role in increasing the proliferation and clonogenicity in GSCs. 
MicroRNA in GA-MSC-Derived Exosomes Increase GSC Tumorigenicity 
 In order to evaluate whether miR-1587 could significantly increase the 
tumorigenicity of GSCs, I conducted in vivo experiments using GSC 20 over-
expressing miR-1587. These experiments are currently in progress, and mice have 
been injected with GSC 20 in 6 groups (n=15/group): untreated GSC 20 controls, 
GSC 20 treated with GA-MSC-derived exosomes, GSC 20 treated with GA-MSC-
derived exosomes plus anti-miR-1587 inhibitor, GSC 20 treated with anti-miR-1587 
inhibitor alone, GSC 20 over-expressing miR-1587, and GSC 20 over-expressing 
miR-scramble. Of the 15 mice, 9 will be followed for survival and then euthanized, 
and 6 will be sacrificed for time point comparison. I expect similar results as those 
described from my in vitro experiments. GSC 20 over-expressing miR-1587 should 
increase tumor burden and decrease median survival when compared to untreated 
GSC 20 controls. Additionally, the increase in tumor burden and decrease in median 
survival should be similar to that of GSC 20 treated with GA-MSC-derived 
exosomes. Moreover, there should be a significant decrease in tumor burden and 
increase in median survival between GSC 20 treated with GA-MSC-derived 
exosomes plus anti-miR-1587. Lastly, there should not be a significant difference in 
tumor burden or median survival when comparing untreated GSC 20 controls to 
GSC 20 treated with anti-miR-1587, and to GSC 20 over-expressing miR-scramble. 
Demonstration of these results would indicate that miR-1587 in GA-MSC-derived 
exosomes has a causal role in increasing the tumorigenicity of GSCs. 
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Figure 40. NCOR1 is down-regulated in GSCs over-
expressing miR-1587. Western blot analysis of the functionality 
of miR-1587 in GSC, demonstrating a baseline expression of 
the predicted miR-1587 target, the nuclear receptor co-
repressor-1 (NCOR1) gene, in GSC controls. Expression of 
NCOR1 is down-regulated with GSCs over-expressing miR-
1587, which is similar to that of treatment with GA-MSC-derived 
exosomes. This down-regulation of NCOR1 expression is 
reversible with the addition of a miR-1587 inhibitor. 
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4.3 Discussion 
 In this chapter I show for the first time that GA-MSC-derived exosomes 
contain highly expressed and highly enriched miRNA, which share conserved 
nucleotide sequences. Furthermore, global analysis of the data from gene 
expression profiling showed that the expression of predicted gene targets of these 
miRNA was down-regulated in GSCs after treatment with GA-MSC-derived 
exosomes. Of the highly expressed and highly enriched exosomal miRNA, only miR-
1587 was able to increase both GSC proliferation and clonogenicity in in vitro 
experiments. Importantly, increased levels of miR-1587 in GSC correlated with the 
down-regulation of NCOR1, a major predicted gene target of miR-1587. 
 The packaging of specific RNA species in exosomes is well established, and 
is now recognized as an ordered, non-random, process. With respect to MSCs, the 
miRNA profiles of secreted exosomes are known to be significantly different from 
that of the parental cell.199-200 This difference includes certain miRNA that are either 
enriched or depleted in MSC-derived exosomes.201 These studies suggest a normal 
physiologic role for the process of miRNA trafficking and packaging into exosomes. 
With regards to cancer, RNA that are preferentially packaged and enriched in 
exosomes are being examined as diagnostic modalites. Exosomes derived from 
cancer cells, termed oncosomes, are viewed as an extension of the tumor itself, and 
the specific RNA profiles are being investigated in order to screen for and diagnose 
many different types of cancer, including prostate, bladder, kidney, liver, colorectal, 
ovarian, lung, breast, leukemia, melanoma and even brain cancers.81,202-210 
Together, these MSC and cancer studies suggest that the enrichment of RNA in 
exosomes is a process that not only occurs under normal physiologic conditions, but 
also in the pathologic processes of cancer.  
 The recognition of specific nucleotide sequences in normal physiologic cell 
biology is well described. For instance, in the process of transcribing a gene, 
transcription factors recognize and bind to certain core promoter regions on the DNA 
strand upstream of the gene, such as the TATA-box sequence of 4-nucleotides.211 
This recognition and binding is essential for subsequent binding of RNA polymerase 
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and initiation of gene transcription.211 Likewise, specific 3-nucleotide-long sequences 
in mRNA transcripts (codons) are then recognized and bound by complementary 
sequences of tRNA carrying specific amino acids.212 This recognition is a key step in 
the ribosomal translation of mRNA into a protein gene product.212 Thus, gene 
expression is reliant upon effective recognition of specific nucleotide sequences. 
Therefore, it is reasonable that nucleotide sequences on miRNA are recognized and 
bound by proteins responsible for the trafficking of RNA into exosomes.  
 The process by which RNA is packaged within exosomes is not well 
established, however there is evidence demonstrating that specific nucleotide 
sequences may provide recognition sites for directing specific RNA species to 
exosomes. Specifically, Batagov, et al., in the study of fibroblast-derived exosomes, 
was the first to demonstrate that the presence of three different 8-nucleotide 
sequences (ACCAGCCU, CAGUGAGC, and UAAUCCCA), present in mRNA and 
pre-miRNA, directed enrichment of these RNA transcripts into exosomes.213 These 
nucleotide motifs were discovered by computational analysis utilizing cluster 
algorithms to identify nucleotide commonalities. Since this initial study, Columba-
Cabezas and colleagues demonstrated that the Gag p17 matrix protein of HIV-1 
contained a 117-nucleotide region that was essential for packing of unspliced HIV-1 
mRNA into exosomes derived from infected cells.214 Without this nucleotide motif, 
HIV-1 mRNA was not incorporated into exosomes, and instead was diverted into 
viral partcles.214 This study highlights the role of a long nucleotide sequence that can 
be recognized as a region for directing mRNA into exosomes. With respect to 
gliomas, Bolukbasi and colleagues, recently demonstrated that a 25-nucleotide 
sequence, with a smaller CTGCC core sequence, that was present in mRNA that 
were highly enriched in exosomes derived from 2 glioblastoma cell lines.71 Fusion of 
this nucleotide motif to non-exosomal mRNA resulted in preferential packaging into 
exosomes. Interestingly, enriched mRNA also contained a binding site for miR-1289 
in their 3’-UTR, which served as a co-enrichment factor once bound.71 This study 
further supports the theory of nucleotide pattern recognition for trafficking of RNA 
species into exosomes. With regard to exosomal packaging proteins, Villarroya-
Beltri, et al., demonstrated the binding of SUMO (small ubiquitin-like modifier) -
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heterogeneous nuclear ribonucleoprotein A2B1 (SUMO-hnRNPA2B1) to specific 
nucleotide motifs on miRNAs.25 Specifically, SUMO-hnRNPA2B1 recognized and 
bound the 4-nucleotide sequence of GGAG on miRNA. Although, SUMOlyation is 
ubiquitin-like, it does not result in protein degradation. Instead SUMO-hnRNPA2B1 
is targeted to exosomes, and consequently enriches miRNA that is bound to it.25 
This study is the only one to describe the protein-mediated trafficking of miRNA into 
exosomes. Interestingly, the GGAG miRNA motif is similar to one of the 4-nucleotide 
sequences identified in my analysis of highly expressed and highly enriched miRNAs 
in MSC-derived exosomes (GGAC). Therefore it is reasonable that specific 
nucleotide sequences of miRNA, combined with GC:UA enrichment, can direct the 
preferential packaging of miRNA into MSC-derived exosomes.   
 The capability of exosomal miRNA to regulate gene expression in recipient 
cells has been established  in various tissues. With regards to the brain, this process 
has been described in both physiologic and pathologic conditions. Specifically, 
Morel, et al., demonstrated that exosomes derived from neurons can affect the 
expression of amino acid transporters in astrocytes.215 The delivery of miR-124a via 
neuron-derived exosomes, increased the expression of glutamate transporter-1 
(GLT1) in recipient astrocytes. Furthermore, the disruption of this communication 
pathway is linked to key changes that occur during the progression of amyotrophic 
lateral sclerosis (ALS).215 More relevant to my work, Li at colleagues, demonstrated 
that exosomes derived from the U251 glioblastoma cell line are able to alter the 
transcriptome of recipient human brain microvascular endothelial cells (hBMVECs).72 
The communication of exosomal miRNA significantly down-regulated the expression 
of 19 genes involved in the maintenance of the blood-brain barrier.72 Together, these 
two studies indicate that cells can utilize exosome-mediated regulation of gene 
expression to modify the surrounding microenvironment. 
 Similar to the designation of genes that inhibits malignant growth as a tumor-
suppressors, there are miRNAs that also inhibit malignant growth and are termed 
tumor-suppressor-miRNAs.216 Specifically, the group of miRNA that were highly 
expressed and highly enriched in GA-MSCs, and thus depleted from GA-MSC-
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derived exosomes, consists of miRNAs that have been shown to have tumor-
suppressor capabilities (Table 7). For example, Tan, et al., demonstrated that miR-9 
inhibits the proliferation of gliomas cells through the down-regulation of the pro-
proliferative cyclic-AMP element binding protein (CREB).217 Additionally, Moncini 
and colleagues, demonstrate that miR-103a has a negative effect on cell growth and 
migration through the down-regulation of cyclin dependent kinas-5R1 (CDK5R1).218 
Similarly, Chen, et al., described the glioma-suppressing role of miR-107, which was 
linked to the down-regulation of cyclin dependent kinase-2 (CDK2) and neurogenic 
locus notch homolog protein-2 (NOTCH2).219 Furthermore, Gu and colleagues 
demonstrated that miR-199a functions as a tumor-suppressor in gliomas by down-
regulating the expression of musculoaponeurotic fibrosarcoma oncogene homolog-B 
(MAFB).220 Lastly, Skalsky, et al., demonstrated that miR-376c is highly expressed in 
normal brain tissue and functions to down-regulate the activin receptor-like kinase-7 
(ALK7) in glioblastoma.221 Each of these studies highlight the relative low expression 
of these tumor-suppressor miRNAs in gliomas. These reports suggest GA-MSCs 
have a repertoire of miRNA that can inhibit glioma growth and invasion, yet do not 
package these tumor-suppressive miRNA into exosomes. Therefore, it is also 
reasonable that oncogenic miRNAs are instead enriched in GA-MSC-derived 
exosomes. The group of enriched miRNA, however have only recently been 
discovered and consequently are not as well characterized as the depleted miRNAs.  
 Similar to the designation of genes that promote malignant growth as 
oncogenes, there are miRNAs that also promote malignant growth and are termed 
onco-miRNAs. However, unlike the group of depleted miRNA from MSC-derived 
exosomes that are tumor-suppressive, the group of highly expressed and highly 
enriched miRNA in MSC-derived exosomes consists of newly identified miRNA that 
have not yet been study, and consequently have no known function. The potential 
for these unstudied miRNA to be onco-miRNAs is suggested by my experimental 
results in which MSC-derived exosomes increased the tumorigenicity of GSCs. 
Given the wide range of genes that one miRNA can target, and the similarly wide 
range of miRNA that can target one gene, the effects of GA-MSC-derived exosomal 
miRNA on GSCs are most likely not attributable to a single miRNA. However, my 
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results indicate that miR-1587 is not only highly expressed and highly enriched in 
MSC-derived exosomes, but is at least one exosomal miRNA that appears to 
mediate the increase in proliferation and clonogenicity of GSCs. My study is also the 
first to describe the targeting and down-regulation of the nuclear receptor co-
repressor-1 (NCOR1) in gliomas by miR-1587. NCOR1 was first identified and 
characterized by Horlein and colleagues in 1995.222 In this study, researchers 
discovered a transcriptional co-regulatory protein that could repress expression of 
gene targets for thyroid hormone receptors and retinoic acid receptors, independent 
of ligand binding. Since the discovery of NCOR1, several other NCORs have been 
identified, and have been shown to function in both normal physiologic and 
pathologic conditions, including cancer.223-225    
 The association of NCOR1 with thyroid hormone receptors and retinoic acid 
receptors suggested a role in both thyroid cancer and retinoblastoma.226-227 Initially 
in 2007, Furuya, et al., demonstrated that a loss of function, or lower cellular 
expression, of NCOR1 resulted in increased proliferation and motility of thyroid 
tumor cells.226 These effects resulted from decreased NCOR1-mediated repression 
of PI3K/AKT signaling, leading to a more aggressive follicular thyroid carcinoma 
phenotype.226 This was the first report linking NCOR1 function to thyroid cancer, and 
it’s designation as a tumor-suppressor gene in this type of hormone-related cancer. 
Recently in 2013, Nazha and colleagues, demonstrated that low expression of 
NCOR1 in the nucleus of retinoblastoma cells increased their proliferation and 
promoted the maintenance of an undifferentiated state.227 This expression pattern 
was also demonstrated in retina-progenitor cells, which supports the role of NCOR1 
as a regulator of cellular differentiation. This study was the first to describe a tumor-
suppressor role for NCOR1 in retinoblastoma, and revealed the cellular localization 
of NCOR1 to be key to its function.227   
 In gliomas, NCOR1 was originally thought to be an oncogene, but recent 
studies have suggested a tumor suppressor role. A study published by Park and 
colleagues in 2007, initially established an oncogenic function for NCOR.228 
Outcomes from this study highlighted the tumor-promoting effects resulting from high 
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expression levels of NCOR in gliomas. These effects were linked to the 
phosphorylation and subsequent shuttling of NCOR out of the nucleus and into the 
cytoplasm. Thus, elevated nuclear expression of NCOR was associated with 
maintenance of an undifferentiated state, and deemed oncogenic in gliomas.228 
However, these researchers were evaluating the NCOR family in the U87 
glioblastoma cell line, and did not distinguish between effects caused by NCOR1 
and NCOR2. Although both co-repressors associate with the same hormone 
receptors, their relative expression levels in the cytoplasm and nucleus are quite 
different, as demonstrated by Campos, et al., in 2010.229 Results from this study 
demonstrated a low expression of NCOR1 in both cytoplasmic and nuclear fractions, 
and high nuclear expression of NCOR2, in tumor cells extracted from 283 patients 
with varying grades of astrocytic gliomas. This study suggests that NCOR2 may 
have an oncogenic function, while NCOR1 has a tumor-suppressor function.229 
Consistent with this concept, in 2013, Heldring, et al., also demonstrated the tumor-
suppressor function of NCOR1 in gliomas, by showing that the knockdown of 
NCOR1 resulted in glioma growth and invasiveness both in vitro and in vivo.230 
Furthermore, decreased expression of NCOR1 correlated with the epithelial-to-
mesenchymal transition in glioblastoma.230 Together, these studies indicate that 
down-regulation of the tumor-suppressor NCOR1 in gliomas, results in the 
promotion of growth and evolution of the malignancy. Therefore, my experimental 
result demonstrating an increase in GSC proliferation and clonogenicity caused by 
miR-1587-mediated down-regulation of NCOR1 is consistent with the literature.    
 My future experiments include linking NCOR1, and thus miR-1587, to the 
increases in GSC tumorigenicity demonstrated in my results. This would involve the 
use of siRNA to knockdown expression of the NCOR1 gene in GSCs, simulating the 
effect of miR-1587 in GA-MSC-derived exosomes. Silencing of NCOR1 with shRNA 
eliminates the non-specific effects that miR-1587 could induce by the down-
regulation of other genes in addition to NCOR1. Given the results from Heldring, et 
al., I expect to find an increase in GSC tumorigenicity when NCOR1 expression is 
suppressed. This result would mirror that of miR-1587 over-expression in GSCs, and 
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GSCs treated with GA-MSC-derived exosomes, thus defining a final biological 
pathway by which GA-MSC-derived exosomes promote gliomas. 
 One of the weaknesses of my study was the further evaluation of only one 
miRNA based on the results from my in vitro experiments. Specifically, I did not 
perform western blot analysis or in vivo studies of miR-3620-5p, which significantly 
increased the proliferation of GSCs, but did not have a significant effect on GSC 
clonogenicity. Additionally, I also did not perform further analysis on miR-1246 which 
increased both GSC proliferation and clonogenicity, but not to a significant degree. 
Further investigation of the predicted gene targets of these two miRNA, combined 
with in vivo studies, may indicate a synergistic tumor-promoting function with miR-
1587. Another weakness in this study was the evaluation of only one predicted gene 
target of miR-1587. Although identification of putative miR-1587 targets has not yet 
been described, verification of its functionality by demonstrating the down-regulation 
of another predicted gene target would better support my in vitro results, classifying 
miR-1587 as an onco-miRNA in MSC-derived exosomes. 
 Conversely, a strength of this study was the utilization of computational 
analysis of the miRNA profiles of BM-MSC-derived and four GA-MSC-derived 
exosomes in order to develop a list of potential oncogenic miRNAs. This process 
was significantly more efficient that a shotgun approach analyzing all miRNA in 
MSC-derived exosomes to identify those which are tumor-promoting. Another 
strength of this study was the use of gene expression profiling to demonstrate the 
down-regulation of predicted gene targets for enriched miRNA, after treatment of 
GSCs with GA-MSC-derived exosomes. This method ensured that the group of 
potential oncogenic exosomal miRNA had a significant effect on the GSC 
transcriptome before conducting in vitro and in vivo experiments. A final strength of 
this study was utilization of an anti-miR-1587 inhibitor to reverse the effects of GA-
MSC-derived exosomes on GSCs in my in vitro experiments. This treatment group 
helped isolate the effects of miR-1587, and ensured that no other exosomal miRNAs 
were responsible for the increases seen in GSC proliferation and clonogenicity.  
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4.4 Conclusions 
 My experimental results demonstrate that GA-MSC-derived exosomes are 
enriched with a specific group of miRNA, as compared to GA-MSCs. Interestingly, 
these enriched miRNA contained specific nucleotide motifs that were common 
among the group, and absent from depleted miRNA. Furthermore, the expression of 
predicted gene targets for the enriched miRNAs, were significantly decreased in 
GSCs after treatment with GA-MSC-derived exosomes. Importantly, the over-
expression of one of the enriched miRNAs (miR-1587) significantly increased both 
proliferation and clonogenicity in GSCs. Finally, a predicted gene targets for this 
specifically enriched miRNA (NCOR1), was decreased after miR-1587 over-
expression in GSCs and after treatment of GSCs with GA-MSC-derived exosomes. 
These results indicate that the mechanism by which GA-MSC-derived exosomes 
promote glioma growth is through the delivery of specific oncogenic miRNA to 
recipient GSCs.  
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Chapter V 
Research Summary 
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Research Summary 
 
 For my thesis work, I hypothesized that GA-MSC-derived exosomes enhance 
the growth and evolution of gliomas. My initial experiments studied the production 
system of GA-MSC-derived exosomes and subsequently characterized their 
proteomic and genomic contents. I then investigated the interaction between GA-
MSC-derived exosomes and GSCs, and showed that GA-MSC-derived exosomes 
increases in the tumorigenicity of GSCs. Finally, I discovered a link between a 
specific miRNA (miR-1587), delivered in GA-MSC-derived exosomes to GSCs, that 
was responsible for the glioma-promoting properties of this intercellular 
communication pathway. This system culminated in the down-regulation of a tumor-
suppressor protein in gliomas (NCOR1), and revealed the onco-potentiating ability of 
GA-MSC-derived exosomes. These results validate my hypothesis and show for the 
first time that stroma-derived exosomes in the glioma microenvironment can 
influence growth and evolution of the malignancy via the delivery of specific miRNA 
to recipient GSCs.   
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5.1 Experimental Conclusions 
 These experimental results are the first to demonstrate the production of 
characteristic exosomes by GA-MSCs. Moreover, the production of GA-MSC-
derived exosomes varies with exposure to different levels of cellular stressors. 
Additionally, GA-MSC-derived exosomes do not contain major proteins or cytokines. 
However, GA-MSC-derived exosomes do contain numerous miRNA with distinct 
profiles compared to parental MSCs. Indeed, a specific group of miRNAs are highly 
expressed in GA-MSC-derived exosomes. These results prove that GA-MSCs are 
capable of producing exosomes whose content have the potential to impact the 
biology of recipient cells. 
 By tracking GA-MSC-derived exosomes utilizing a GFP-CD63 fusion protein, I 
showed that GSCs can internalize GA-MSC-derived exosomes. More importantly, I 
demonstrate for the first time that GA-MSC-derived exosomes significantly increase 
the proliferation and clonogenicity of GSCs in vitro. Moreover, GA-MSC-derived 
exosomes can significantly increase the tumorigenicity of GSCs in vivo. 
Furthermore, pre-treatment of GSCs with GA-MSC-derived exosomes increases 
tumor burden and decrease median survival. These results prove that GA-MSC-
derived exosomes can interact with GSCs to influence their biology. 
 My experimental results demonstrate that GA-MSC-derived exosomes are 
enriched with specific miRNAs, as compared with parental GA-MSCs. Interestingly, 
enriched miRNAs contained specific nucleotide motifs that were common among the 
group. Furthermore, the expression of predicted gene targets for the enriched 
miRNAs was significantly decreased in GSCs after treatment with GA-MSC-derived 
exosomes. Importantly, the over-expression of one of the enriched miRNAs (miR-
1587) increased both proliferation and clonogenicity in GSCs. Finally, one of the 
predicted gene targets for this specifically enriched miRNA (NCOR1), was 
decreased with both miRNA over-expression in GSCs and GSCs treated with GA-
MSC-derived exosomes. These results indicate that an enriched miRNA in GA-
MSC-derived exosomes alters the expression of a tumor-suppressor in gliomas 
leading to increased glioma growth. 
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5.2 Research Significance 
 The significance of my thesis work is far-reaching, from demonstrating 
exosomal communication in the tumor microenvironment to describing selective 
miRNA packaging, to reporting the loss of tumor-suppressor activity in gliomas. 
These results describe several aspects of cellular biology that have never before 
been shown in gliomas. Moreover, my results demonstrate the impact of the glioma 
microenvironment on tumor growth, which can potentially be targeted by adjunct 
therapy in the future. 
 The results of my studies elucidated the role of exosomal communication in 
the tumor microenvironment. My results indicates that exosomes from the 
microenvironment contribute to maintaining a supportive niche for malignant growth 
and suggest that this mode of interaction between the tumor stroma and the tumor 
propagating cells may be consistent throughout all solid tumor cancer types. 
Therefore one of the major impacts of my work is the necessity to consider the 
influence of tumor stroma-derived exosomes in glioma growth and future therapeutic 
strategies to inhibit this tumor-supporting property. 
 My project also described the packaging of selective miRNA into GA-MSC-
derived exosomes. My results suggest that incorporation of certain materials into 
exosomes is cell-of-origin specific, and may be influenced by interactions with 
neighboring cells. Additionally, the packing of specific exosomal miRNA suggests 
that a particular effect can be induced in recipient cells. Therefore, another major 
impact from my work is the gene-altering capabilities of tumor stroma-derived 
exosomes which must be taken into account in the process of glioma progression. 
 Lastly, my research demonstrated the specific down-regulation of a tumor 
suppressor gene in glioma via delivery of GA-MSC-derived exosomes. Therefore, a 
final major impact from my work is that the tumor stroma provides a nurturing 
environment by regulating gene expression in tumor propagating cells, which must 
be taken into account during the treatment of aggressive gliomas. 
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5.3 Future Investigations 
 The intercellular exosomal communication between GA-MSCs and GSCs is 
only one pathway in a complex network of interactions between cells within the 
glioma microenvironment. In the future, I plan to expand my investigations of the 
tumor niche to include evaluating the role of GSC-derived exosomes in modulation 
of the surrounding stroma. Specifically, I will examine the effects of GSC-derived 
exosomes on GA-MSCs, brain microvascular endothelial cells (BMVEC), astrocytes 
and microglia. Given the function of these cells, this communication network may 
serve to transform the microenvironment to better promote glioma growth. Thus, 
GSC-derived exosomes may play a role in the recruitment of MSCs from the bone 
marrow, breakdown of the blood-brain barrier, invasion into brain parenchyma, and 
immunosuppression within the tumor. As an extension of this study, I would also 
investigate the diagnostic and prognostic applications of GSC-derived exosomes in 
serum. Some of these processes have been demonstrated in other cancer types, 
and their description in gliomas is necessary. 
 Another direction that I would like to explore is the nucleotide motifs in miRNA 
that may target them for enrichment into exosomes. Although this study is not 
necessarily associated with gliomas, or cancer, it has a much broader scope for 
defining the process of exosomal miRNA packaging. This investigation would involve 
identifying conserved nucleotide sequences present in enriched miRNA from 
exosomes from a variety of cell types. Extensive computational and cluster analysis 
would be necessary for an effective and efficient approach to this experimentation. 
Once key motifs were identified, artificial mutations in these sequences should result 
in the decreases expression of previously enriched miRNA in exosomes. 
Additionally, encoding of these sequences in previously exosome depleted miRNA, 
should result in their enrichment into exosomes. Positive results of this study would 
have a broad range of applications, including cancer therapy and diagnostics. 
 New functions of exosomes are constantly being described, and my results 
combined with those of future studies will aid in the full understanding of this novel 
paracrine signaling mechanism. 
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